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 When subjected to increased workload, the heart responds metabolically by 
increasing its reliance on glucose and structurally by increasing the size of myocytes. 
Whether changes in metabolism regulate the structural remodeling process is unknown. 
A likely candidate for a link between metabolism and growth in the heart is the 
mammalian target of rapamycin (mTOR), which couples energy and nutrient metabolism 
to cell growth. Recently, sustained mTOR activation has also been implicated in the 
development of endoplasmic reticulum (ER) stress. We explored possible mechanisms 
by which acute metabolic changes in the hemodynamically stressed heart regulate 
mTOR activation, ER stress and cardiac function in the ex vivo isolated working rat 
heart. Doubling the heart’s workload acutely increased rates of glucose uptake beyond 
rates of glucose oxidation. The concomitant increase in glucose 6-phosphate (G6P) was 
associated with mTOR activation, endoplasmic reticulum (ER) stress and impaired 
vii 
contractile function. Both rapamycin and metformin restored glycolytic homeostasis, 
relieved ER stress and rescued contractile function. G6P and ER stress were also 
downregulated with mechanical unloading of failing human hearts. Taken together, the 
data support the hypothesis that metabolic remodeling precedes, triggers, and sustains 
structural remodeling of the heart and implicate a critical role for G6P in load-induced 
contractile dysfunction, mTOR activation and ER stress. In general terms, the 
intermediary metabolism of energy providing substrates provides signals for the onset 
and progression of hypertrophy and heart failure.  
 
 
 
 
 
 
 
viii 
TABLE OF CONTENTS 
 
DEDICATION……………………………………………………….……………........iii 
ACKNOWLEDGMENTS…………………………………………….……………...…iv 
ABSTRACT……………………………………………………………….....................vi 
LIST OF FIGURES……………………………………………………….....................xiii 
LIST OF TABLES…………………………………………………….…….................xvi 
LIST OF ABBREVIATIONS………………………....................................................xvii 
CHAPTER 1: INTRODUCTION 
1.1. Scope Of The Dissertation…….……………………………….................2 
1.2. Regulation Of Cardiac Metabolism………………………………………4 
1.3. Structural and Functional Responses To Altered Hemodynamic Load…12 
1.4. mTOR Signaling Pathway……………………………............................18 
1.5. Endoplasmic Reticulum Stress………………………………….............23 
CHAPTER 2: MATERIALS AND METHODS 
 2.1 Rationale For Methods Used…………………………............................29 
 2.2  Materials………………………………...............………………………30 
  2.2.1. Rodent Experiments 
   2.2.1.1. Mice………………………….........................................30 
ix 
   2.2.1.2. Rats……………...….......................................................31 
  2.2.2. Left Ventricular Tissue Samples From Heart Failure Patients…...33 
  2.2.3. Perfusion Apparatus For The Isolated Working Heart…………...34
  2.2.4. Liquid Scintillation Counter For Determination Of Radioactivity 35 
  2.2.5. Spectrophotometer For Assessment Of Intracellular Metabolite 
  Content………….....................................................................................37 
  2.2.6. Western Blotting Apparatus And Sources Of Antibodies…..........37 
  2.2.7. Sequence Analyzer For Quantitatve RT-PCR…………………....38
  2.2.8. Miscellaneous Equipment……………………………...…………38 
 2.3 Methods……………………………………………………....................39 
  2.3.1. PET And MRI Imaging…………………………………..............39 
  2.3.2. Isolated Working Rat Heart Perfusions……...………………...…41
   2.3.2.1. Perfusion Buffers And Protocols…..…………..……….43 
   2.3.2.2. Determination Of Cardiac Power, Rates Of Glucose   
   Uptake, Rates Of Glucose Oxidation………………….…….…..46 
  2.3.3. Spectrophotometric Enzymatic Metabolite Analyses…………….48 
  2.3.4. Western Immunoblotting…………………………………………51 
  2.3.5. QRTPCR………………………………….....................................52 
  2.3.6. Statistical Analysis……………………………………...…...........55 
x 
CHAPTER 3: LOAD-INDUCED mTOR ACTIVATION IS MEDIATED BY 
CHANGES IN GLUCOSE METABOLISM 
 3.1  Introduction…………………………………….......................................57 
 3.2  Results…………………………………...................................................61 
  3.2.1. Metabolic Remodeling Precedes Structural Remodeling In  
   Response to Increased Workload In Vivo……………………….61 
  3.2.2. Load-Induced mTOR Activation Requires Glucose……………64 
  3.2.3. mTOR Activation Impairs Contractile Function At High  
   Workload……………………………..........................................68 
  3.2.4 Workload-dependent Mismatch Between Rates Of Glucose  
              Uptake And Oxidation At High Workload…………..………….70 
  3.2.5.  Glucose 6-Phosphate Accumulates At High Workload as a  
   Consequence of a Mismatch Between Rates of Glucose Uptake 
   and Oxidation................................................................................72 
  3.2.6.  Accumulation Of Glucose 6-Phosphate Analogue 2-Deoxy- 
   Glucose 6-Phosphate Activates mTOR……………………...….74 
  3.2.7. Glucose 6-Phosphate-dependent mTOR Activation is Mediated 
   By Downregulation of AMPK………………….……………….76 
  3.2.8  Metformin Inhibits mTOR Activation and Rescues Contractile 
   Function at High Workload…………………………….……….78 
xi 
  3.2.9 Glucose Phosphorylation Modulates mTOR Activation in vivo 
   (TAC and ACSL-/- mice) …………………………...……….…83 
  3.2.10 Mechanically unloading failing human hearts with LVAD  
  reduces Glucose 6-Phosphate levels and mTOR Activation……………86 
 3.3 Discussion………………………………….............................................88 
CHAPTER 4: SUSTAINED mTOR ACTIVATION INDUCES ER STRESS 
 4.1 Introduction……………………………………………….......................98 
 4.2 Results…………………………………………………….....................100 
  4.2.1 Load-induced ER Stress Requires Glucose and mTOR 
   Activation…………………………………………...................100 
  4.2.2 Pretreatment with Rapamycin or Metformin Inhibits ER Stress 
   and Prevents Contractile Dysfunction at High Workload…..…104 
  4.2.3 Markers of ER Stress are Downregulated in Failing Human 
   Hearts Following Mechanical Unloading with LVAD……..…108 
  4.2.4 Role of Autophagy in G6P-mediated mTOR activation…..…..109 
 4.3 Discussion…………………………………………….….....................110 
 4.4 Limitations of the Isolated Working Heart as a Model……….……….114 
CHAPTER 5: CONCLUSIONS AND PERSPECTIVE………..………………..…....116 
BIBLIOGRAPHY………………………………………………………………….….125 
xii 
VITA………………………………………………………………..……………....…154 
 
  
 
 
xiii 
LIST OF FIGURES 
Figure 1.1 Multiple metabolic fates of glucose…………..……………………...…..8 
Figure 1.2 Changes in glucose metabolism in the hypertrophied heart. ………...…11 
Figure 1.3 Plasticity of the Heart. …………………………………………….....…13 
Figure 1.4 Components of an LVAD……………………………………………….17 
Figure 1.5 mTORC Signaling Pathway……………………………………….……21 
Figure 1.6  Endoplasmic Reticulum (ER) Stress Response. ………………………..25 
Figure 2.1 Modification of perfusion apparatus developed by Taegtmeyer, Hems 
  and Krebs. ………………………………………………………………36 
Figure 2.2 Cannulation of the left atrium and aorta. …………………………….…43 
Figure 2.3  Sample Standard Curve Used to Quantify mRNA Transcript levels of 
  ER stress markers. ……………………………………………...………55 
Figure 3.1 Proposed activation of the mTOR signaling pathway by glucose………58 
Figure 3.2 Metabolic remodeling precedes structural remodeling in hearts  
  subjected to high workload in vivo. ………………………………….…62 
Figure 3.3 Functional changes accompany metabolic changes in response to  
  high workload. ……………………………………………………….…64 
Figure 3.4 In hearts subjected to high workload, glucose activates mTOR………...66 
xiv 
Figure 3.5 In the presence of mixed substrates, mTOR signaling is activated and 
  G6P levels are elevated at high workload……………………….……...67 
Figure 3.6 In hearts subjected to high workload, cardiac power is impaired  
  when glucose is the only substrate. Rapamycin rescues contractile  
  function………………………………………………………………….69 
Figure 3.7 Rates of glucose uptake exceed rates of glucose oxidation in response 
  to high workload. Rapamycin corrects this mismatch…………………..71 
Figure 3.8 G6P accumulates in response to high workload…………………...……73 
Figure 3.9 Glucose analogues used in isolated working heart perfusions………….75 
Figure 3.10 Increased phosphorylation of mTOR and p70S6K is associated with 
  increased hexose 6-phosphate levels in hearts perfused with 2DG…….75 
Figure 3.11 G6P-dependent mTOR activation is mediated by AMPK   
  downregulation. …………………………………….………………..…77 
Figure 3.12 G6P-dependent mTOR activation is inhibited by metformin….………..79 
Figure 3.13 Metformin treatment corrects the mismatch between rates of glucose 
  uptake and oxidation at high workload and blunts G6P accumulation…80 
Figure 3.14 Metformin treatment improves cardiac power at high workload……….81 
Figure 3.15 Early metabolic changes are associated with G6P accumulation in  
  hearts subjected to high workload in vivo…………………………........84 
xv 
Figure 3.16 Early metabolic changes are associated with mTOR activation in  
  hearts subjected to high workload in vivo………………………….….84 
Figure 3.17 G6P accumulation correlates with mTOR activation in the ACSL -/- 
  mouse. …………………………………………………………………85 
Figure 3.18 Mechanical Unloading of Failing Human Hearts Reduces G6P  
  accumulation and mTOR activation……………………………………87 
Figure 4.1 Hearts perfused with glucose at high workload show evidence for ER
  stress. …………………………………………………………………102 
Figure 4.2 Lactate release is unchanged with workload or rapamycin treatment 
  in isolated working hearts perfused with glucose…………………….103 
Figure 4.3 ER Stress is relieved with rapamyin, metformin, and PBA. Relief of ER 
  stress improves contractile function in hearts perfused with glucose 
  at high workload. ………………………………………………..……105 
Figure 4.4  Transcriptome analysis of stressed hearts treated with rapamycin,  
  metformin, and phenylbutyrate……………………………………..…107 
Figure 4.5 Mechanically unloading failing human hearts reduces markers of ER 
  stress. …………………………………………………………………108 
Figure 4.6 Markers of autophagy are unchanged with rapamycin treatment in  
  hearts stressed with an acute increase in workload……………………109 
 
xvi 
LIST OF TABLES 
 
Table 1.1  Comparison of energy yields from various fuels per molecule  
  oxidized. ……………………………………………………………….…6 
 
Table 2.1 Clinical Data for 11 Patients with Idiopathic Dilated Cardiomyopathy 
  placed on Left Ventricular Assist Device (LVAD)…………………..…34 
Table 2.2 Ex vivo perfusion protocols used to study glucose activation of mTOR 
  signaling at high workload………………………………………………45 
 
Table 3.1 Levels of ATP, ADP, and AMP in ex vivo perfused hearts…………..…82 
 
 
 
 
 
 
 
xvii 
LIST OF ABBREVIATIONS 
 
2DG  2-Deoxy-Glucose 
3OMG  3-O-Methyl-Glucose 
4EBP1  4E-Binding Protein 1 
AcAc+P Acetoacetate + Propionate 
ACC  Acetyl-CoA Carboxylase 
ACE  Angiotensin Converting Enzyme 
ACSL  Long-Chain Acyl Coenzyme A Synthetase 
AMPK  5’ Adenosine Monophosphate Activated Kinase 
ATF6  Activating Transcription Factor 6 
ATP  Adenosine Triphosphate 
BSL  Baseline 
CHOP  CCAAT/Enhancer-Binding Protein Homologous Protein 
DEPTOR DEP-Domain-Containing mTOR-Interacting Protein 
ECG  Electrocardigraphy 
ECL  Enhanced Chemiluminescence 
xviii 
EDTA  Ethylenediaminetetraacetic acid 
EDV  End Diastolic Volume 
EGTA  Ethylene Glycol Tetraacetic Acid 
EIF2  Eukaryotic Initiation Factor 2 
ER  Endoplasmic Reticulum 
ERP72  Endoplasmic Reticulum Protein 72 
ESV  End Systolic Volume 
G6P  Glucose 6-Phosphate 
G6PD  Glucose 6-Phosphate Dehydrogenase 
GAP  GTPase Activating Protein 
GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase 
GFAT  Glutamine:Fructose-6-Phosphate-Amidotransferase 
Glc  Glucose 
GLUT  Glucose Transporter 
GRP  Glucose Regulated Protein 
GS  Glutathione Synthase 
GSH  Glutathione (reduced) 
xix 
GSK  Glycogen Synthase Kinase 
GSSG  Glutathione Disulfide (oxidized) 
GTP  Guanosine Triphosphate 
HK  Hexokinase 
HOPE  Heart Outcomes Prevention Evaluation 
HW/BW Heart Weight/Body Weight 
IGF  Insulin-like Growth Factor 
IP  Intraperitoneal 
IRE-1  Inositol Requiring Enzyme-1 
JNK  c-Jun N-terminal Kinase 
LDH  Lactate Dehydrogenase 
LVAD  Left Ventricular Assist Device 
LVEDD Left Ventricular End Diastolic Dimension 
LVEDV Left Ventricular End Diastolic Volume 
LVEF  Left Ventricular Ejection Fraction 
LVESV Left Ventricular End Systolic Volume 
MCAD Medium Chain Acyl Dehydrogenase 
xx 
ME  Malic Enzyme 
MF  Metformin 
MK  Myokinase 
MLST8 Mammalian Lethal with Sec13 Protein 8 
MRI  Magnetic Resonance Imaging 
mSIN1  mammalian Stress-Activated Protein Kinase-Interacting Protein 
mTOR  mammalian Target Of Rapamycin 
mW  Milliwatt 
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NCS  Noncarbohydrate Substrates 
OGT  O-linked N-acetylglucosamine Transferase 
OMC  Oxoglutarate-Malate Carrier 
PBA  Phenylbutyrate 
PCr  Phosphocreatine 
PCR  Polymerase Chain Reaction 
PDI  Protein Disulfide Isomerase 
PDK  Pyruvate Dehydrogenase Kinase 
xxi 
PERK  PKR-like ER Kinase 
PET  Positron Emission Tomography 
PGI  Phosphoglucoisomerase 
PI3K  Phosphotidylinositol 3-kinase 
PK  Pyruvate Kinase 
PKC  Protein Kinase C 
PPAR  Peroxisome Proliferator Activated Receptor 
PRAS40  Proline-Rich Akt Substrate 40 kDa  
RAPTOR Regulatory-Associated Protein Of mTOR 
REMATCH Randomized Evaluation of Mechanical Assistance for the Treatment of 
  Congestive Heart Failure 
RHEB  Ras Homolog Enriched in Brain 
RICTOR Raptor-Independent Companion of TOR 
RNA  Ribonucleic Acid 
SEM  Standard Error of the Mean 
SERCA Sarcoendoplasmic Reticulum Calcium ATPase 
SGK  Serum Glucocorticoid Regulated Kinase 
TAC  Transverse Aortic Constriction 
xxii 
TSC  Tuberous Sclerosis Complex 
U  Units 
XBP1  X-box Binding Protein 
1 
 
 
 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
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1.1 Scope of the Dissertation 
 This thesis addresses molecular mechanisms of heart failure. Why is this 
important?  
 First, heart failure is a leading cause of death in the United States (Roger, Go et 
al. 2011). While there is a decline in the incidence of coronary artery disease, we 
observe a relentless increase in mortality from heart failure. Nearly 5 million Americans 
suffer from heart failure. Each year over a million patients are hospitalized because of it 
and nearly 300,000 die from heart failure in the United States alone. Moreover, death 
from heart failure exceeds death from all forms of cancer combined (Roger, Go et al. 
2011). 
 Secondly, despite many advances in cardiovascular medicine, current treatment 
has not seen a major drug since the advent of diuretics and neurohormonal antagonists. It 
is expected that the number of heart failure patients will double in the next five years. 
The development of heart failure is often preceded by cardiac growth manifested as the 
hypertrophy of the cardiomyocyte. Decompensated systolic heart failure is a loss of 
functional heart muscle in response to increased hemodynamic stress on the heart from 
hypertension, valvular heart disease, anemia, or prior myocardial infarction. However, 
the molecular mechanisms that drive the stressed heart to hypertrophy and ultimately fail 
or die remain incompletely understood.  
 Before the stressed heart progresses into failure, it undergoes a series of 
characteristic changes. The heart ‘remodels’ both metabolically and structurally. 
Metabolically, hearts augment glucose uptake and oxidation, and structurally, hearts 
3 
grow by underdoing hypertrophy. When stressed, the heart can increase its mass by up to 
100% through hypertrophic remodeling (Hill and Olson 2008). Modulation of the 
remodeling process is recognized as a potentially auspicious approach in the prevention 
and treatment of heart failure.  
 The structural remodeling process has been studied extensively in an unbiased 
approach using microarray gene expression profiling. With this technology, key gene 
clusters involved in calcium handling proteins, sarcomeric proteins, mitochondrial 
proteins, cell death, inflammation, and the extracellular matrix have been identified 
(Steenman, Chen et al. 2003; Asakura and Kitakaze 2009). Unfortunately, strategies 
designed to prevent apoptotic cell death, inflammation, (Sandler and Dodge 1963) and 
excessive degradation of the extracellular matrix (Mann 1999) have yielded little 
therapeutic benefit. Therefore, a better understanding of the remodeling process is 
necessary to develop more effective treatment for heart failure.  
 The lab has previously demonstrated that metabolic remodeling precedes 
structural remodeling in the heart (Taegtmeyer and Overturf 1988) and proposed that, 
when stressed, metabolic remodeling (which is potentially reversible) regulates 
functional and structural remodeling (which may be irreversible) (Taegtmeyer, Golfman 
et al. 2004). I therefore set out to investigate whether the metabolic remodeling process 
regulates functional and structural changes that accompany cardiac growth and explore 
whether these changes are preventable. 
 The work presented in my dissertation provides evidence in support of the 
hypothesis that metabolic remodeling precedes, triggers, and sustains structural 
4 
remodeling of the heart. The rationale is based on the foundation that in all eukaryotic 
cells the target of rapamycin (TOR) signaling pathway couples energy and nutrient 
metabolism to the execution of cell growth (Sandler, Dodge et al. 1963). Specifically, I 
identify dysregulated glucose metabolism and subsequent G6P accumulation as 
mediators of load-induced mTOR activation, ER stress, and contractile dysfunction. The 
study highlights the importance of intermediary metabolism as a source of signals for 
cardiac growth and demonstrates the potential to reduce internal work and improve 
cardiac efficiency by targeting the metabolic axis in load-induced heart disease. 
 Understanding the mechanism and consequences of G6P-mediated mTOR 
activation will help identify novel metabolic targets to reverse contractile dysfunction in 
the hemodynamically stressed heart. Given the limitations of current heart failure 
treatment there is an urgent need for a more targeted approach to treating the early 
metabolic changes in the stressed heart. I propose that my project has taken an important 
step in this direction. 
 
1.2 Regulation of Cardiac Metabolism 
  
 In order to fully appreciate the ability for metabolic signals to activate cardiac 
growth pathways, a brief review of the regulation of cardiac metabolism is needed. Like 
any organ in a living organism, the mammalian heart liberates energy contained in 
organic molecules to support its physiologic function (Holmes 1992). Critical steps are 
phosphorylation of ADP and subsequent hydrolysis of ATP. Rates of ATP turnover in 
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the heart are greater than rates of ATP turnover in any other organ, and so are the rates 
of substrate utilization and oxygen consumption (Taegtmeyer 1994). Hence, the need for 
early restoration of coronary blood flow in acute coronary syndrome and myocardial 
infarction. 
 Research on the metabolism of energy providing substrates for the heart began in 
a major way when Bing performed the first coronary sinus catheterization and identified 
fatty acids, glucose, and lactate as the major sources of fuel for the heart (Bing, Vandam 
et al. 1947). It was appreciated early on that the heart is a metabolic ‘omnivore’, i.e. an 
organ with that has the capacity to utilize multiple substrates in combination to support 
contractile function (Taegtmeyer 1994). Initially, by calculating oxygen extraction ratios 
and respiratory quotients (the ratio of the number of molecules of carbon dioxide 
produced per oxygen taken up for a given substrate), Bing showed that the heart in the 
fasted and unstressed state of the body oxidizes primarily fatty acids. Later, it was 
confirmed more precisely that indeed the normal mammalian heart generates 60-90% of 
its ATP from the oxidation of fatty acids and 10-40% from the oxidation of pyruvate by 
glycolysis and lactate oxidation (Bing, Siegel et al. 1954; Wisneski, Gertz et al. 1987).  
It has been reasoned that the healthy, unstressed heart preferentially metabolizes fatty 
acids because each molecule yields significantly more reducing equivalents (H), and 
hence ATP compared to glucose, lactate, or pyruvate (Table 1.1).  
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 While the unstressed heart primarily oxidizes fatty acids, the increased energy 
requirements of hearts subjected to high workload are met by the oxidation of 
carbohydrates (Goodwin, Taylor et al. 1998). A classic explanation for this phenomenon 
is based on the fact that the heart oxidizes the most efficient substrate for a given 
situation (Taegtmeyer, Hems et al. 1980). Despite the higher number of reducing 
equivalents per molecule, fatty acids are less oxygen-efficient (lower P/O ratio, see 
Table 1.1) and require up to 40% more oxygen to produce the same amount of ATP 
(Korvald, Elvenes et al. 2000). Because oxygen consumption increases linearly with 
workload in the heart, when oxygen becomes a limiting factor at high workload the heart 
preferentially oxidizes glycogen, glucose, and lactate (Goodwin, Taylor et al. 1998). 
Similarly, it has been proposed that the poorly oxygenated fetal heart also preferentially 
oxidizing glucose and lactate for this reason.  
 Our fundamental understanding of intermediary glucose metabolism started in 
1860 with the identification of glycolysis by Pasteur (Holmes 1992). By 1937, the details 
of the glycolytic pathway were discovered by Embden and Meyerhof. Later that year, 
Table 1.1 Comparison of energy yields from various fuels per molecule oxidized. 
Adapted and expanded from The Heart: Physiology and Metabolism (Opie 1991, 
page 211). 
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Krebs and Johnson demonstrated that pyruvate formed succinate and closed the loop of 
the citric acid cycle (Krebs and Johnson 1937). Since then, investigators have discovered 
more and more of the complexity of intermediary glucose metabolism, the multiple 
metabolic fates of glucose, as well as the potential involvement of glucose in pathways 
that regulate intracellular signaling in the heart. These topics will now be briefly 
reviewed.  
 Glucose enters the cardiomyocyte down its concentration gradient from the 
coronary circulation by facilitated (or carrier-mediated) diffusion through glucose 
transporters (GLUT). The two major GLUTs in the heart include the insulin-independent 
GLUT1 transporter found on the sarcolemma and the insulin-dependent GLUT4 
transporter, which is translocated to the sarcolemma in the presence of insulin. Increases 
in workload also promote glucose transporter translocation to the plasma membrane 
(Wheeler, Fell et al. 1994).  
 The bulk of glucose taken up by the cardiomyocyte and phosphorylated enters 
the glycolytic pathway and generates pyruvate, which is oxidized in the mitochondria via 
the Krebs cycle. The Krebs cycle provides the reducing equivalents for the formation of 
ATP under aerobic conditions. Glucose 6-phosphate can potentially enter a number of 
other pathways, as well, including glycolysis, glycogen synthesis pathway, pentose 
phosphate pathway, hexosamine biosynthetic pathway, and aldose reductase/polyol 
pathway (Fig. 1.1). Glucose metabolism through these accessory pathways provides 
some energy,  maintains the biological functions of the cardiomyocyte, and plays a role 
in intracellular cardiac growth signaling, as described below.  
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 Changes in the rate of glycolysis and glucose oxidation can modulate 
intracellular signaling pathways by altering levels of free ADP, AMP, and the PCr:ATP 
ratio in both the rodent and human heart (Neubauer 2007) (Nascimben, Ingwall et al. 
2004). A hallmark of the failing heart is a reduction in the PCr:ATP ratio (Neubauer 
2007), which is thought to contribute to the decline in contractile function accompanying 
heart failure. On a molecular level, a reduction of the [ATP]/[AMP] ratio is known to 
modulate the activity of AMP Kinase (AMPK), the ‘metabolic fuel gauge’ of the cell, 
which regulates metabolic enzymes, ion channels, gene expression, and intracellular 
signaling pathways of protein turnover through various phosphorylation events. Most 
Figure 1.1 Multiple metabolic fates of glucose 6-phosphate. Upon entry into the 
cardiomyocyte, glucose can be metabolized through a number of different pathways. 
Many of these pathways have been demonstrated to regulate intracellular growth 
signaling either in the heart or in other organs. 
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notably, AMPK phosphorylates ACC, reduces malonyl CoA, and increases fatty acid 
oxidation. AMPK phosphorylation also promotes glucose transporter translocation to the 
plasma membrane (Young, Li et al. 2005). 
 Although heart muscle lacks the enzyme glucose 6-phosphatase, glucose 6-
phosphate (G6P) can undergo multiple metabolic fates (Fig. 1.1). G6P can be converted 
into UDP-N-acetylglucosamine (UDPGlcNac) by the enzyme glutamine:fructose-6-
phosphate-amidotransferase (GFAT), the rate-limiting enzyme of the hexosamine 
biosynthetic pathway. UDPGlcNac serves as the substrate for O-GlcNacylation of 
proteins by the enzyme O-GlcNac transferase  (OGT). Like phosphorylation reactions, 
post-translational modification of proteins and transcription factors by O-GlcNacylation 
holds potential to regulate a number of intracellular signaling pathways (McClain 2002). 
Indeed, both gene expression of the rate limiting enzyme GFAT (Young, Yan et al. 
2007) and O-linked –N-acetylglucosamine transferase are known to be elevated in 
mouse models of heart failure (Watson, Facundo et al. 2010).  
 The pentose phosphate pathway provides an additional avenue for glucose upon 
entry into the cardiomyocyte (Fig 1.1). Our laboratory has previously demonstrated that 
up to 20% of glucose taken up by the heart enters the pentose phosphate pathway 
(Goodwin, Cohen et al. 2001). The pathway is divided into the oxidative and non-
oxidative arms (Horecker and Mehler 1955). The oxidative arm consumes G 6-P using 
glucose 6-phosphate dehydrogenase (G6PD). The non-oxidative arm of the pentose 
phosphate pathway produces xylulose-5-phosphate, an important building block for 
nucleic acid synthesis but less well appreciated for its ability to induce the expression of 
metabolic genes in the liver such as pyruvate kinase (Nishimura and Uyeda 1995; 
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Doiron, Cuif et al. 1996). G6PD enzyme activity is upregulated in cardiac hypertrophy 
(Zimmer 1992). The significance of this may relate to increased ribose formation and/or 
modulation of oxidative stress.  
 G6P can also be enzymatically converted to sorbitol by aldose reductase with a 
concomitant decrease in NADPH, as well (Hwang, Kaneko et al. 2004). NADPH is a 
required cofactor for the regeneration of the reduced form of the anti-oxidant 
glutathione, and its depletion would exacerbate intracellular oxidative stress. 
Intracellular oxidative stress triggers a number of intracellular signaling pathways 
including those involved in growth signaling (Alexander, Cai et al. 2010). When present 
in excess, glucose is also converted to glycogen by the enzyme glycogen synthase. 
Glycogen synthase is phosphorylated by glycogen synthase kinase 3β (GSK-3β) which 
itself is a regulatory kinase that modulates cardiac growth (Haq, Choukroun et al. 2000). 
It is conceivable that this kinase plays a dual role in modulating both glucose 
metabolism in the heart and cardiac growth, as well. I will explore the role of 
intermediary glucose metabolites and assess whether these accessory pathways regulate 
cardiac growth in the stressed heart. Changes in glucose metabolism known to occur 
with cardiac hypertrophy are summarized in (Fig. 1.2). Interestingly, the same changes 
are present in the unloaded, atrophied heart (Depre, Shipley et al. 1998) (Doenst, 
Goodwin et al. 2001). 
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Figure 1.2 Changes in glucose metabolism in the pressure-overload induced 
hypertrophied heart. Pathways marked in green have been shown to increase, 
pathways marked in red have been shown to decrease, and pathways marked in blue 
have been shown to not change in the hypertrophied heart. Black arrows, boxes, and text 
represent pathways that  have yet to be extensively studied in the hypertrophied heart. 
GFAT, glutamine fructose-6-phosphate amidotransferase; GLUT, glucose transporter; 
LDH, lactate dehydrogenase; ME, malic enzyme; NADH, reduced nicotinamide adenine 
dinucleotide; OMC, oxoglutarate-malate carrier; PC, pyruvate carboxylase; MCT, 
monocarboxylate transporter. Modified from Kolwicz and Tian Cardiovascular 
Research 2011.  Reprinted with permission from Oxford University Press. 
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1.3 Structural and Functional Responses of the Heart to Altered Hemodynamic 
Load 
 
Development of Cardiac Hypertrophy: 
 A wide variety of both physiological and pathological stimuli can promote 
cardiac growth. Physiological cardiac hypertrophy (growth) occurs during postnatal 
growth, pregnancy, and with prolonged vigorous exercise. Pathological cardiac 
hypertrophy is induced by cardiac injury, hypertension, or neurohormal stimulation (Fig. 
1.3). In the nineteenth century, cardiac growth was first thought to merely represent a 
step in the development of heart failure when Sir William Osler characterized it as a 
phenomenon that “takes place slowly and results from degeneration and weakening of 
the heart muscle” (page 98). (Osler W. The Principles and Practice of Medicine. New 
York: Appleton, 1892.)  
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 Nearly a century later, data from the Framingham Heart Study recognized left 
ventricular hypertrophy as a true risk factor for heart failure and arrhythmias (Levy, 
Garrison et al. 1990; Koren, Devereux et al. 1991). Why does it occur? According to the 
law of LaPlace:  
Figure 1.3 Plasticity of the Heart. The healthy human heart structurally remodels in 
response to both increases and decreases in load. A reduction in load leads to atrophy 
and an increase in load leads to hypertrophy. Sustained increases in pathological load 
are known to lead to heart failure and ventricular arrythmias (Hill and Olsen, NEJM 
2008). Reprinted with permission from Massachusetts Medical Society. 
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wall tension = (pressure) x (radius)/(wall thickness) 
 Accordingly, increased wall thickness in the heart reduces ventricular wall 
tension in hearts subjected to high workload (Sandler and Dodge 1963; Grossman, Jones 
et al. 1975). However, cardiac hypertrophy secondary to valvular heart disease is 
associated with contractile dysfunction irrespective of the degree of valvular damage 
(Gunther and Grossman 1979) (Huber, Grimm et al. 1981) (Krayenbuehl, Hess et al. 
1988) suggesting that its development may not follow as linear of a pattern as the law of 
LaPlace would suggest. Is hypertrophy necessary to compensate for increased cardiac 
work? In preclinical studies, contractile function is preserved in hearts subjected to high 
workload and treated with small molecular inhibitors of intracellular growth signaling 
pathways (Hill, Karimi et al. 2000), suggesting that cardiac growth may not be 
necessary. It remains difficult to ascertain whether cardiac growth is initially a necessary 
adaptive response in the stressed heart or not. 
 On a molecular level, the heart has different mechanisms to respond to acute and 
sustained increases in hemodynamic load. When subjected to an acute increase in 
workload, changes in cardiac metabolism occur instantaneously, as discussed above. 
Similarly, even acute changes in workload trigger changes in the post-translational 
modification of proteins, as well. Most notably, increased workload regulates the 
activation of membrane-bound receptors such as G-protein coupled receptors leading to 
downstream changes in the protein phosphorylation and activation of growth signaling 
pathways (Molkentin and Dorn 2001). Ultimately, sustained increases in workload and 
activation of these signaling pathways lead to changes in gene expression. Previous 
members of the lab have reviewed the transcriptional changes in metabolic genes 
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(GLUT1, GLUT4, PPAR-alpha,PDK2, MCAD, ACC) and contractile protein (myosin 
heavy chain) isoforms, in the stressed heart (Rajabi, Kassiotis et al. 2007).     
 Modulation of myocardial growth and hypertrophy without adversely affecting 
contractile function is increasingly recognized as a potentially auspicious approach in the 
prevention and treatment of heart failure. A better understanding of the intracellular 
signaling cascades that drive the hypertrophic process are necessary before this will be 
possible. This begs the question: which signals and intracellular signaling pathways 
drive the normal heart to hypertrophy and ultimately fail? Can they be targeted? 
Molkentin et al have extensively reviewed the highly coordinated manner by which a 
number of signaling cascades interact to regulate cardiac growth signaling (Molkentin 
and Dorn 2001; Dorn and Force 2005). However, only the mammalian target of 
rapamycin (mTOR) signaling pathway is known to be both activated in the heart in 
response to increased workload and responsive to changes in a cell’s metabolic milieu. I, 
therefore, focused our attention on studying whether the metabolic changes known to 
occur in hearts subjected to increased workload regulate mTOR activation in the stressed 
heart. 
 
Regression of Cardiac Hypertrophy: 
 A number of studies have demonstrated that regression of left ventricular 
hypertrophy improves outcome in patients with cardiovascular disease. In the Heart 
Outcomes Prevention Evaluation (HOPE) trial, patients with either known high-risk 
vascular disease or diabetes and at least one additional cardiovascular risk factor 
16 
(hypertension, dyslipidemia, cigarette use, microalbuminuria) were randomly assigned to 
receive either an angiotensin converting enzyme (ACE) inhibitor or placebo daily for 2.5 
years (Yusuf, Sleight et al. 2000). Up to a decade later, analyses from the study 
identified that inhibition or even regression of cardiac hypertrophy by ACE inhibitor 
therapy lowered the risk for several cardiovascular endpoints including death and 
progression to heart failure, whereas persistence of cardiac hypertrophy (despite similar 
blood pressure changes) predicted an adverse outcome (Mathew, Sleight et al. 2001). 
 Mechanical reduction of load in patients with heart failure also improves 
cardiovascular hemodynamics, functional status, and quality of life. In the Randomized 
Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure 
(REMATCH) study, patients with New York Heart Association Class III or IV heart 
failure were randomized to either optimal medical management or implantation of a left 
ventricular device (Rose, Gelijns et al. 2001) (Fig. 1.4). At the time of final analysis, 
LVAD implantation was associated with a forty eight percent reduction in the risk of 
death from any cause and improvement in quality of life compared to optimal medical 
therapy.  
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 The effects of LVAD implantation on cardiac metabolism have been investigated 
extensively at the transcriptional and post-translatoinal levels (Razeghi, Myers et al. 
2002) (Margulies, Matiwala et al. 2005). Previous studies in our lab have observed a 
trend for decreased myocardial glycogen content in failing human hearts after 
mechanical unloading (Razeghi and Taegtmeyer 2004) and more recently, proteomic 
analysis has revealed an upregulation of proteins involved in glycolysis, energy, and 
Figure 1.4 Components of an LVAD. The LVAD mechanically reduces the 
load on failing heart. Circulating blood enters the LVAD from the left ventricle 
through the inflow cannula. The prosthetic left ventricular then pumps the 
blood through the outflow cannula and into the (ascending) aorta. The pumping 
chamber is placed within the abdominal wall or peritoneal cavity. A 
percutaneous drive exits the skin and connects the device to external battery 
packs worn on shoulder holsters and a system controller worn on the belt. 
Image reprinted with permission from Massachusetts Medical Society (Rose, 
Gelijns et al. 2001). 
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oxidative metabolism in LVAD supported patients.(de Weger, Schipper et al. 2011) 
Taken together, these data suggest improved metabolic capacity with mechanical 
unloading with LVAD implantation. This conclusion is supported by reports that have 
suggested improvements in respiratory capacity in mitochondrial isolated from hearts of 
patients supported by an LVAD (Lee, Doliba et al. 1998). 
  
1.4 mTOR Signaling Pathway 
 
 In mammalian tissue, mTOR links nutrient availability to growth in muscle, 
adipose, liver, and hypothalamus (Howell and Manning 2011). Cardiac growth can occur 
directly in response to nutrient availability in the Burmese python, which exhibits a 40% 
increase in ventricular mass within 48 hours of consuming a large meal (Andersen, 
Rourke et al. 2005; Riquelme, Magida et al. 2011) and I therefore wondered whether it 
occurs in the stressed heart in an mTOR-dependent manner, as well.   
 Load-induced protein synthesis and cardiac growth is regulated mTOR, a highly 
conserved member of the phosphatidylinositol 3 kinase (PI3 kinase) superfamily that 
regulates cell growth by initiating protein translation and by inducing ribosomal 
biogenesis (Crespo and Hall 2002) (Rohde, Heitman et al. 2001). Research on mTOR 
began when the drug rapamycin, an inhibitor of T cell proliferation and potent 
immunosuppressant, was serendipitously isolated from a strain of Streptomyces 
hygroscopius from soil collected in Rapa-Nui (Easter Island) in the 1970’s (Crespo and 
Hall 2002). Rapamycin is now an FDA-approved immunosuppressant for preventing 
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graft rejection or re-stenosis after angioplasty, and rapamycin is actively being used in a 
number of cancer clinical trials to reduce tumor growth (Garza, Aude et al. 2002) 
(Huang and Houghton 2003). Whether in fungi, T-cells, vascular smooth muscle or 
cancer cells, the primary action of rapamycin is inhibition of cell growth. The protein 
responsible for rapamycin action was first identified in yeast and called TOR (target of 
rapamycin) (Kunz, Henriquez et al. 1993). By analyzing gene expression in yeast cells 
exposed to rapamycin, it was discovered that TOR mediates protein synthesis and was 
regulated by nutrient availability in yeast (Cardenas, Cutler et al. 1999). Indeed, in 
eukaryotic organisms the ability to alter growth according to nutrient availability is 
essential for survival.  
 Studies undertaken to elucidate the mechanism by which rapamycin inhibits 
mTOR revealed that the mTOR kinase actually nucleates two major protein complexes – 
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Schmelzle and Hall 
2000). mTOR complex 1 (mTORC1) contains the scaffolding protein regulatory-
associated protein of mTOR (raptor) as well as mammalian lethal with Sec13 protein 8 
(mLST8), the proline-rich Akt substrate 40 kDa (PRAS40), and DEP-domain-containing 
mTOR-interacting protein (Deptor) and regulates cell growth. mTOR complex 
(mTORC2) consists of mLST8, the scaffolding protein raptor-independent companion of 
TOR (rictor), mSIN1 proteins, and the protein observed with rictor (Protor) and 
cytoskeleton regulation and cell survival (Laplante and Sabatini 2009). The components 
of each respective protein complex are necessary for either upstream regulation, 
complex formation, or downstream signal activation and function. Most notably, 
however, mTORC2 is distinguished from mTORC1 by its resistance to inhibition with 
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acute rapamycin treatment (Sarbassov, Ali et al. 2006). In fact, only prolonged 
rapamycin treatment (an important consideration for my experiments, see Chapter 3) 
inhibits mTORC2 complex assembly and reduces the levels of mTORC2 below those 
needed to maintain downstream Akt signaling both in vitro (Sarbassov, Ali et al. 2006), 
and in samples from patients with acute myeloid leukemia (Zeng, Sarbassov dos et al. 
2007) (Fig. 1.5). mTORC2 is also known to activate PKCalpha to regulate actin 
reorganization and SGK1 to regulate FOXO (Powell and Delgoffe 2010), however the 
regulation of these proteins by rapamycin has yet to be studied. Our insight into 
upstream activators of mTORC2 is limited, as well. However, a wealth of information 
exists on both upstream activators of mTORC1 and downstream consequences, which 
will now be reviewed. 
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 In the unstressed heart, mTOR and its downstream targets, 4EBP1 and p70S6K 
(S6K1), are inhibited by the upstream protein Ras homolog enriched in brain (Rheb). 
Rheb is a small GTPase that requires binding of GTP to interact with and activate mTOR 
(Long, Ortiz-Vega et al. 2005). Upstream of Rheb is the tuberous sclerosis complex 
(TSC), which is composed of the proteins TSC1 and TSC2 (Inoki, Corradetti et al. 
2005). TSC2 is the GTPase-activating protein (GAP) for Rheb and when bound by 
TSC1, it promotes the conversion of Rheb-GTP to Rheb-GDP, thereby inhibiting mTOR 
(Inoki, Li et al. 2003). Therefore, differential phosphorylation of TSC2 regulates 
mTORC1 activation (Huang and Manning 2008).  
 Growth factors, branched chain amino acids, reactive oxygen species (ROS), and 
genotoxic stress are all upstream regulators of mTORC1 (Sengupta, Peterson et al. 
2010). Growth factors such as insulin and IGF-1 activate mTORC1 by differentially 
phosphorylating TSC2 to suppress its GAP activity on Rheb in a PI3K-dependent 
manner (Tee, Anjum et al. 2003) and amino acids activate mTORC1 by promoting 
mTOR interaction with lysosomal Rheb-GTP (Sancak, Peterson et al. 2008) (Sancak, 
Bar-Peled et al. 2010) whereas ROS and genotoxic stress inhibit mTOR by stabilizing 
the TSC complex and TSC2’s GAP activity on Rheb (Budanov and Karin 2008; 
Alexander, Cai et al. 2010). I, therefore, felt it was plausible that metabolic regulation of 
mTOR activation in the heart also occurred in a TSC or Rheb-dependent manner.  
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1.5 Endoplasmic Reticulum Stress 
  
 A consequence of sustained activation of mTOR is increased and uncontrolled 
protein synthesis leading to endoplasmic reticulum (ER) stress. In the unstressed 
cardiomyocyte, proteins synthesized in the rough endoplasmic reticulum are efficiently 
folded. Molecular chaperones located within the ER facilitate this process by identifying 
hydrophobic regions of misfolded or unfolded proteins and refolding them into 
functioning proteins in order to prevent toxic protein aggregate formation (Ron and 
Walter 2007). The chaperone protein glucose-regulated protein 78 (GRP78) also serves 
as a gauge for sensing protein homeostasis within the endoplasmic reticulum. When the 
concentration of misfolded or unfolded proteins is low, GRP78 remains bound to the 
three ER proximal effectors – PKR-like ER kinase (PERK), insolitol-requiring enzyme-1 
(IRE-1), and activating transcription factor-6 (ATF6). When bound by GRP78, these 
proximal effectors remain inactive. When subjected to hemodynamic stress (continued 
pumping against high workload), mTOR activation promotes cardiac growth by 
increasing rates of protein synthesis. Up to one third of all proteins synthesized in the 
cardiomyocyte are shuttled through the endoplasmic reticulum (Blobel 2000). When 
hypertrophic stimuli are sustained, rates of protein synthesis exceed the protein folding 
capacity of the ER leading to the accumulation of unfolded and misfolded proteins 
beyond the ER’s capacity to cope with the load (Okada, Minamino et al. 2004; 
Glembotski 2008). The hydrophobic regions of unfolded and misfolded proteins attract 
GRP78. GRP78 translocation from the luminal surface of IRE-1, ATF6, and PERK 
activates all three proximal effectors. One of the earliest consequences of proximal 
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effector activation is the transcriptional activation of ER stress-response genes including 
chaperone proteins (GRP78, GRP94), disulfide isomerases (ER protein 72, ERp72), and 
calcium binding proteins (calreticulin). Interestingly, the promoter site of most ER stress 
response genes has an ER stress response element, suggesting that transcriptional 
induction is highly conserved (Thuerauf, Hoover et al. 2001). Increased expression of 
these genes enhances the protein folding capacity of the ER. Moreover, if its 
transcriptional activation is sufficient to alleviate the acute increase in ER stress, excess 
GRP78 once again binds the proximal effectors and signals the resolution of the ER 
stress response.  
 In both human and animal studies, contractile dysfunction in the hypertrophic 
and failing heart has been linked to elevated glucose uptake (Taegtmeyer and Overturf 
1988) (Zhang, Duncker et al. 1995) (Bishop and Altschuld 1970) in an insulin-
independent manner (Allard, Wambolt et al. 2000). It is also known that normal 
contractile function of the cardiomyocyte requires proper protein folding. However, 
whether elevated glucose uptake is associated with contractile dysfunction in hearts 
subjected to high workload as a result of improper protein folding has yet to be studied. 
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Figure 1.6 Endoplasmic Reticulum (ER) Stress Response. When the protein 
folding capacity of the ER is exceeded, the ER stress response is activated. Adapted 
from Glembotski JMCC 2008. Reprinted with permission from Elsevier Publishing 
Company.  
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  If the ER stress response is sustained, PERK activation inhibits the activation of 
the protein translational machinery via the phosphorylation of eukaryotic initiation factor 
2 α (eIF2α) and IRE1 activation ultimately leads to apoptosis via the activation of JNK 
and caspase-12.   
 Ischemia is a known activator of the ER stress response. Mouse hearts subjected 
to ischemia and reperfusion ex vivo demonstrate increased GRP78 expression as do 
myocytes surrounding the infarct zone in mice subjected to myocardial infarction in vivo  
(Thuerauf, Marcinko et al. 2006). The mechanism is thought to involve AMPK 
activation (Terai, Hiramoto et al. 2005) and lead to the activation of autophagy-mediated 
cell death (Takagi, Matsui et al. 2007). The ER stress response is also activated in 
hypertrophied and failing mouse hearts that have been subjected to increased workload 
by transverse aortic constriction (Okada, Minamino et al. 2004). Whether load-induced 
mTOR activation, ER stress and contractile dysfunction are metabolically regulated in 
the heart remains unknown.  
 Systemic metabolic disorders such as diabetes are associated with ER stress in 
skeletal muscle, liver, and adipocytes (Hotamisligil 2010) (Eizirik, Cardozo et al. 2008). 
Indeed, changes in glucose or fatty acid metabolism in vitro regulate the ER stress 
response. Whether changes in cardiac metabolism regulate (or are regulated by) ER 
stress remain to be investigated. Because chemical chaperone treatment has been shown 
to alleviate ER stress and correct glucose homeostasis in mouse models of diabetes 
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(Ozcan, Yilmaz et al. 2006), it is plausible that it holds great promise in targeting heart 
disease, as well.  
 The consequences of ER stress on cardiac function and metabolism form the 
second part of my thesis. They have led us to speculate that relief of ER stress improves 
metabolism and efficiency of the heart. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
29 
2.1 Rationale for Methods Used and Overall Strategy 
 
 The structural and functional response to increased workload has been extensively 
studied in the murine transverse aortic constriction (TAC) model (Rockman, Ross et al. 
1991). How the metabolic responses to increased workload may regulate these changes 
has yet to be investigated. In order to answer this question systematically we used three 
different models – C57BL/6J mouse hearts subjected to increased workload in vivo by 
TAC, Sprague-Dawley rat hearts subjected to increased workload ex vivo using the 
isolated working heart apparatus, and left ventricular tissue samples from human heart 
failure patients before and after implantation of a left ventricular assist device (LVAD).  
 First, in studies initiated in the laboratory of our collaborator Bijoy Kundu at the 
University of Virginia Medical School, in vivo FDG-PET and MRI were performed 
simultaneously in mice subjected to TAC for upto four weeks to serially image changes 
in metabolism, structure and function in response to increased cardiac workload. Using 
this model, it was established that metabolic remodeling (enhanced glucose uptake) and 
contractile dysfunction precede structural remodeling (growth and dilation of the left 
ventricle) of the heart when subjected to increased workload. Second, we systematically 
manipulated workload and substrate supply individually used the isolated working rat 
heart ex vivo to elucidate the mechanisms for the observed phenomena in vivo. The 
isolated working rat heart permitted a dynamic minute-by-minute assessment of 
metabolism and function and allowed for assessment of intracellular metabolites and 
activation of relevant signaling pathways at the end of the perfusion. The ex vivo isolated 
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working heart model was also chosen because it gave us complete control over 
workload, substrate concentration and hormone supply. Third, we analyzed left 
ventricular tissue from failing human heart muscle before and after mechanical 
unloading with a left ventricular assist device to correlate our findings to the failing 
human heart, as well. Thus, in contrast to the prevailing strategies (from the bedside to 
the bench) we went from the bench to the bedside to test whether findings in ex vivo 
models are relevant for the failing heart in vivo. The following materials and methods 
were required to carry out these studies. 
 
2.2 Materials 
 
2.2.1 Rodent Experiments 
2.2.1.1 Mice 
 For our in vivo imaging studies, male C57BL/6J mice (8-9 weeks of age) 
obtained from Charles River Laboratories (Raleigh, NC) were subjected to sham 
operation or transverse aortic constriction (TAC) to induce pressure-overload 
hypertrophy by our collaborators at The University of Virginia Medical School using 
methods previously described (Liao, Takashima et al. 2003). During each imaging 
protocol, left ventricular pressure measurements were performed using a Mikro-tip 
Catheter Transducer (Model SPR-671, Size 1.4F, Millar Instruments Inc., Houston, TX) 
connected to Millar and PowerLab hardware and ADI Software (AD Instruments Inc., 
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Colorado Springs, CO). Throughout the experiment heart rate, respiration, and body 
temperature were recorded with a physiological recorder (SA Instruments, Inc., model 
1025L, Stony Brook, NY), and the ECG were monitored (Blue Sensor, Ambu Inc., Glen 
Burnie, MD) and stored for further analysis later. The SAI 1025L was also used to 
maintain the animal’s core body temperature at 37oC. Positron Emission Tomography 
(PET) with the fluorinated glucose tracer analogue 2-deoxy-2-[18F] fluoro-D-glucose and 
Magnetic Resonance Imaging (MRI) were sequentially performed in anesthetized 
animals. PET imaging was performed in a Focus 120 micro PET scanner (Siemens 
Molecular Imaging Inc., Knoxville, TN) to assess changes in metabolism. 150-200 µL of 
18.5-37 MBq FDG solution (IBA Molecular, Sterling VA) was injected intravenously 
into the mice over a period of one minute prior to imaging. Arterial blood samples were 
used for input function estimation.  Mice were also imaged using a 7T Bruker-Siemens 
Clinscan MRI system for structural and functional analyses of the heart. The MR images 
were analyzed using the ARGUS software package (Siemens Medical Systems, 
Erlangen, Germany) for left ventricular end systolic volume (LVESV) and left 
ventricular end diastolic volume (LVEDV) while left ventricular ejection fraction 
(LVEF) was computed from the traced borders. 
 
2.2.1.2 Rats 
 For our ex vivo studies, male Sprague-Dawley rats (387 ± 11g) were obtained 
from Harlan Laboratories (Indianapolis, IN) and housed in the Animal Care Center of 
The University of Texas Medical School at Houston under controlled conditions (23 ± 
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1oC; 12-h light/12-h dark cycle) prior to experimentation. The animals received standard 
laboratory chow (LabDiet® Rodent Diet 5001 containing as a percentage of total 
calories: 28 % protein, 60 % carbohydrate and 12 % fats) and water ad libitum and were 
given at least 48 hours to acclimatize to the facility before they were used in 
experiments.  
 Through the course of this project, two subsets of rats received pharmacological 
agents before they were sacrificed. The first subset of rats received either the mTOR 
inhibitor rapamycin (4 mg/kg/d) or vehicle control (propylene glycol) by oral gavage for 
7 days prior to the experiments. We have previously shown that the timing, dose, and 
delivery of the drug is effective in inhibiting mTOR in the heart  (Sharma, Guthrie et al. 
2007). The second subset received either metformin (250 mg/kg/day or 500 mg/kg/day) 
or vehicle control (saline) intraperitoneally for 7 days prior to sacrifice. Others have 
shown before us that the delivery of metformin by IP injection activates AMPK in the 
heart (Gundewar, Calvert et al. 2009; Benes, Kazdova et al. 2011). Prior to perfusion, all 
animals were anesthetized with chloral hydrate (300 mg/kg/kg).  
 Reflexes were tested in all four limbs prior to incision to ensure sufficient sedation. 
A midline incision was then made to each animal and heparin (200U) was injected 
directly into the inferior vena cava immediately before opening the thoracic cavity to 
ensure proper anticoagulation. Hearts were then quickly removed and transferred into 
ice-cold saline. After cannulation, hearts were perfused in the working mode as 
described before (Taegtmeyer, Hems et al. 1980) and as will be described later. 
 At the conclusion of each perfusion protocol, hearts were freeze-clamped while 
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still beating with aluminum tongs cooled in liquid nitrogen (Wollenberger and Schulze 
1961). A portion of frozen heart tissue was used for dry weight calculations and the 
remainder used for molecular analyses.  
 
2.2.2. Left Ventricular Tissue Samples from Heart Failure Patients 
 Myocardial biopsy samples were obtained from the hearts of 11 non-diabetic 
patients with idiopathic dilated cardiomyopathy referred to the Texas Heart Institute (Dr. 
O.H. Frazier) for heart transplantation at the time of placement of left ventricular assist 
device (LVAD) and at the time of removal after a mean duration of 254±63 days on 
mechanical support. Table 2.1 provides further details on the patients assessed in this 
study. Because mTOR is known to be activated by insulin and many diabetic patients are 
hyperinsulinemic, only non-diabetic patients were studied. A reduction in LVEDD in 
each patient was used to confirm unloading.  
 Tissue from the left ventricular apex was obtained during LVAD implantation 
and again from the same heart during explantation when each patient received a heart 
transplant. Tissue samples were immediately frozen in liquid nitrogen and stored at -
80oC for metabolic and molecular analyses.  
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2.2.3. Perfusion Apparatus for the Isolated Working Heart 
 The perfusion apparatus used in this project was nearly identical to the one 
previously described (Taegtmeyer, Hems et al. 1980). In a modification of the method 
developed by Taegtmeyer et al., in this project the apparatus was assembled in the non-
recirculating mode to prevent the accumulation of lactate, the end product of glycolysis 
and a carbohydrate substrate that would confound our data.  
 The glassware used to assemble the perfusion apparatus was designed by Dr. 
Heinrich Taegtmeyer and made by Mr. Peter Brooks (Ducklington, Oxon, England). The 
apparatus (Fig. 2.1) consisted of (a) A reservoir containing fresh perfusate, (b) Watson 
Marlow 505S peristaltic pump (Watson Marlow Wilmington, MA), which circulated the 
perfusate through the apparatus, (c) 5 µm Millipore filter (Millipore Billerica, MA), 
Table 2.1 Clinical Data for 11 Patients with Idiopathic Dilated Cardiomyopathy. 
Abbreviations: LVAD = left ventricular assist device, LVEDD = left ventricular end 
diastolic dimension, EF = ejection fraction. Data are presented as the mean ± SEM. 
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which filtered out any debris that may have precipitated out of the perfusate, (d) multi-
bulb oxygenator (connected to an external oxygen tank) (e) oxygen sensor, (f) perfusion 
chamber, which housed the cannulated heart, (g) compliance chamber, (h) aortic 
overflow reservoir, (i) coronary overflow reservoir, (j) Langendorff reservoir, and (k) 
reservoir for metabolized perfusate. Each piece of glassware was taken down, 
disconnected from its tubing and submerged in Chromerge (Sigma Aldrich, St Louis, 
MO) at the end of the day daily to prevent protein and bacterial contamination of the 
glassware (Fanburg, Posner Biochim Biophys Acta1969) (Fig. 2.1). 
 The glassware was water-jacketed and circulated with water in the opposite 
direction of the perfusate at a constant temperature of 37o by a C10 immersion circulator 
(Haake GmbH, Karlsruhe, Germany). The water temperature was measured using a YSI 
Tele-thermometer (YSI, Yellow Springs, Ohio). The perfusate circulated between pieces 
of glassware through PVC tubing (VWR, West Chester, PA), which was replaced daily. 
The PVC tubing and glassware were flushed out with 4L of ddH2O in between 
experiments. 
 Aortic pressures were continuously registered throughout each perfusion with a 
Millar Mikro-Tip Catheter Transducer (Model #SPR-524, size 2.5F) attached to a Millar 
Transducer Balance, model TBC-500 (Millar Instruments Co, Houston, TX). The signal 
was transmitted to a MacLab/4e AD instrument and recorded, stored, and analyzed using 
MacLab software, chart v3.3.5 (AD Instruments Inc., Colorado Springs, CO).  The 
following parameters were recorded: heart rate, systolic and diastolic pressures, and 
mean aortic pressure.  
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2.2.4 Liquid Scintillation Counter for Determination of Radioactivity 
 Ultima Gold liquid scintillation cocktail (Perkin Elmer, Waltham, MA) was 
added to coronary effluent samples in a 25 mL glass or PVC scintillation vial and read in 
Figure 2.1 Modification of perfusion apparatus developed by Taegtmeyer, 
Hems and Krebs. The apparatus consisted of a (a) reservoir containing fresh 
perfusate, (b) Watson Marlow 505S peristaltic pump, (c) 5 µm Millipore filter, (d) 
multi-bulb oxygenator, (e) oxygen sensor, (f) perfusion chamber, (g) compliance 
chamber, (h) aortic overflow reservoir, (i) coronary overflow reservoir, (j) Langendorff 
reservoir, and (k) reservoir for metabolized perfusate.  
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a Packard Model 2200 liquid scintillation counter (Packard Instruments, Warrenville, IL) 
to measure radioactivity. Radioactive decay was measured by the scintillation counter in 
counts per minute, which was then converted into disintegrations per minute. Samples 
were stored in the dark overnight prior to reading to correct for liquid sctintillation 
cocktail autoilluminescence. Both [U-14C]glucose and [2-3H]glucose were obtained from 
Perkin Elmer (Waltham, MA). 
 
 2.2.5 Spectrophotometer for Assessment of Intracellular Metabolite Content 
 All metabolite analyses were performed on a Shimadzu UV1600 UV-visible 
Spectrophotometer (Tokyo, Japan).  Enzymes necessary for metabolite analyses, 
including hexokinase and glucose 6-phosphate dehydrogenase used for measuring 
glucose 6-phosphate, were purchased from Sigma Aldrich (St. Louis, MO).  
 
2.2.6 Western Blotting Apparatus and Sources of Antibodies 
 Mini-PROTEAN Tetra Cell electrophoresis system and Trans-Blot SD Semi-Dry 
Transfer Cell (Bio-Rad, Hercules, CA) were used to separate proteins from heart lysates 
and transfer them onto a nitrocellulose membrane (GE Healthcare Life Sciences, 
Pittsburgh, PA). Proteins were detected using Amersham ECL Plus, also purchased from 
GE Healthcare Life Sciences.  
 Antibodies for PI3K, AKT 1/2, TSC2, mTOR, RAPTOR, p70S6K1, 4EBP1, AMP 
kinase, Acetyl CoA Carboxylase (ACC), phospho-PI3K p85 (Tyr458)/p55 (Tyr199) 
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phospho-Akt1/2 (Ser473), phospho-mTOR (Ser2448), phospho-p70S6K (Thr389), 
phospho-4EBP1 (Thr70), (phospho-AMPKinase (Thr172), phospho-ACC (Ser79), 
phospho-TSC2 (Ser 939), and phospho-RAPTOR (Ser 792) were obtained from Cell 
Signaling (Beverly, MA). Antibody for glucose-regulated protein 78 (GRP78), glucose-
regulated protein 94 (GRP94), and ER protein 72 (ERp72) were purchased from Enzo 
Life Sciences (Plymouth Meeting, PA) and GADD153 was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). GAPDH was used to normalize for protein loading 
(Research Diagnostics, NJ).  
  
2.2.7 Sequence Analyzer for Quantitatve RT-PCR 
 Absolute quantification of gene expression was completed using an ABI Prism 
7000 Sequence Detection System (Foster City, CA). The ABI 7000 calculates absolute 
transcript numbers by comparing the number of cycles necessary to meet a fluorescence 
threshold in the sample to the number of cycles needed in standard amounts of RNA 
over a 105 range (standard curve method). Taqman probe chemistry was utilized to 
generate fluorescence by uncoupling the fluorogenic dye molecule and the quencher 
moeity found on a nucleic acid probe by Taq polymerase during each PCR cycle. 
 
2.2.8 Miscellaneous Equipment 
 Revco -80oC freezer (Thermo Scientific, Asheville, NC) and -20oC freezer 
(Sanyo Scientific, Bensenville, IL) for sample and reagent storage, NanoDrop ND-1000 
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spectrophotometer (Nanodrop Technologies, Wilmington, DE) for RNA concentration 
assessment, Polytron tissue homogenizer (Brinkman Instruments, Westbury, NY), Ohaus 
AS120 scale (Florham Park, NJ), Eppendorf desktop centrifuge Model 5415C 
(Hamburg, Germany), Isotemp shaking water bath (Fisher Scientific, Waltham, MA), 
and 2EG gravity convection oven (Precision Scientific, Chicago, IL) for dry heart 
sample preparation. 
 
 2.3 Methods 
 
2.3.1 PET and MRI Imaging 
 Male C57BL/6J mice (8-9 weeks of age) were subjected to sham operation or 
transverse aortic constriction (TAC) to induce pressure-overload hypertrophy and 
housed in a 12 h light/12 h dark cycle and given standard laboratory chow and water ad 
libitum at The University of Virginia Medical School. Mice were serially imaged 1 day, 
2 weeks, and 4 weeks after either sham or TAC surgery by the Kundu lab at the 
University of Virginia Medical School. Prior to imaging, animals were fasted overnight 
with access to water. All experiments were performed in compliance with the Guide for 
the Care and Use of Laboratory Animals, published by the National Institutes of Health 
and were conducted under protocols approved by the Animal Care and Use Committee 
at the University of Virginia. On the day of imaging, each mouse was anesthetized with 
3% Isoflurane and maintained at 1-2% Isolflurane. A Mikro-tip Catheter Transducer was 
then placed in the right carotid artery under stereo-magnification and advanced through 
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the aorta until the tip was positioned in the left ventricle to make left ventricular pressure 
measurements.  Heart rate and cardiac pressure were continuously monitored 
throughout. Body temperature was maintained at 37oC with a warming blanket. 
 Positron Emission Tomography (PET) with [18F] FDG  and Magnetic Resonance 
Imaging (MRI) were sequentially performed in anesthetized animals. PET imaging was 
performed in a Focus 120 micro PET scanner (Siemens Molecular Imaging Inc., 
Knoxville, TN) to assess changes in metabolism. The protocol was initiated by injecting 
150-200 µL of 18.5-37 MBq FDG solution intravenously over a period of one minute. 
The net FDG influx constant, Ki (1/min), was measured over a period of 4 weeks. 
Determination of Ki is considered a robust index of glucose transport and 
phosphorylation (Nguyen, Mossberg et al. 1990). Throughout the procedure heart rate, 
respiration, and body temperature were recorded with a physiological recorder (SA 
Instruments, Inc., model 1025L, Stony Brook, NY), and the ECG was monitored (Blue 
Sensor, Ambu Inc., Glen Burnie, MD). All of the signals were sent to a single SA 
Instruments software interface, which was configured to trigger data acquisition based 
on the ECG. The SAI 1025L was also used to maintain the animal’s core body 
temperature at 37oC.  
 Mice were also imaged using a 7T Bruker-Siemens Clinscan MRI system for 
structural and functional analyses of the heart. After once again being anesthetized, the 
mouse was placed prone inside the radiofrequency coil, and the ECG leads were 
connected to an ECG monitoring module (SA Instruments, Inc., Stony Brook, NY). An 
ECG-triggered, 2D cine gradient echo pulse sequence was used (Berr, Roy et al. 2005) 
with a slice thickness of 1 mm and a zero-filled, in-plane resolution of 100x100 µm2. 
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During each session, the entire LV was imaged with 6-7 contiguous short-axis slices. 
The MR images were analyzed using the ARGUS software package (Siemens Medical 
Systems, Erlangen, Germany) for LVESV, LVEDV, and LVEF was computed from the 
traced borders. Epicardial contours were also traced at the end-diastolic and end-systolic 
phases to compute LV mass (Vinnakota and Bassingthwaighte 2004). This was divided 
by the body weight to obtain the HW/BW ratios. 
 
2.3.2. Isolated Working Rat Heart Perfusions 
 Isolated hearts were perfused using the isolated working heart apparatus, as 
described previously (Taegtmeyer, Hems et al. 1980; Goodwin, Taylor et al. 1998). 
Hearts were removed from the thoracic cavity and placed in ice-cold Krebs-Henseleit 
buffer (25 mM NaHCO3, 2.54 mM CaCl2, 1.18 mM MgSO4, 1.18 mM KH2PO4, 4.75 
mM KCl, 118.5 mM NaCl). Upon isolation and cannulation of the aorta onto the 
apparatus, hearts were initially perfused in the Langendorff mode with Krebs-Henseleit 
buffer equilibrated with 95:5% O2:CO2 to flush residual blood out of the ventricles and 
allow the heart to resume regular contraction. Following cannulation of the left atrium, 
hearts were switched to the non-recirculating working mode and perfused for 60 
minutes.   
 The afterload against which each heart pumped is proportional to the height of 
the aortic overflow reservoir. Under steady state conditions, hearts were perfused at a 
physiological workload (afterload set to 100 cm) for 60 minutes. Hearts subjected to a 
high workload were perfused for 30 minutes at a physiological workload followed by 30 
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minutes at an increased workload (afterload raised to 140 cm H2O, plus 1µM 
epinephrine bitartrate added to the perfusate). The preload, determined by the height of 
the oxygenator’s overflow above the left atrium, was set to 15 cm H2O for all perfusions. 
At the end of each 60 minute perfusion, hearts were freeze-clamped while still beating 
with aluminum tongs cooled in liquid nitrogen (Wollenberger and Schulze 1961).  
 The isolated working heart apparatus was selected as a model because it provides 
numerous advantages over in vivo, in vitro, and other ex vivo approaches available. A 
number of in vivo models have manipulated glucose entry into the heart by 
overexpressing a transporter (Liao, Jain et al. 2002) or knocking out a receptor (Belke, 
Betuing et al. 2002) necessary for glucose transport in the heart. However, in each 
instance, the insult to the animal is both supraphysiological and accompanied by 
compensatory changes in the heart that make it difficult to delineate the role of glucose 
in cardiac growth signaling in a heart stressed in a physiological manner. In vitro 
systems simply do now allow for modulating workload in the cardiomyocyte nor to 
accurately measure contractile function. In other ex vivo models such as the Langendorff 
preparation, the amount of perfusate pumped by the ventricles is far less than 
physiological and contractile function cannot accurately assessed (Neely, Liebermeister 
et al. 1967). On the other hand, there is a near-physiologic level of work performed by 
the heart in the ex vivo working perfusion system (Taegtmeyer, Hems et al. 1980). 
Moreover, hemodynamic stress can be applied to hearts using our system by subjecting 
hearts to an ex vivo increase in workload, and both contractile function and changes in 
substrate flux can be assessed in real time, as well. 
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2.3.2.1. Perfusion Protocols and Buffers 
 Fresh buffer was made daily. All perfusion buffers included Krebs Henseleit 
buffer (25 mM NaHCO3, 2.54 mM CaCl2, 1.18 mM MgSO4, 1.18 mM KH2PO4, 4.75 
mM KCl, 118.5 mM NaCl). Buffer was prepared by adding a 20X stock solution 
containing all electrolytes with the exception of CaCl2 and NaHCO3 to double distilled 
Figure 2.2 Cannulation of the left atrium and aorta. This photograph of 
the perfusion apparatus highlights the placement of the isolated rat heart 
within the perfusion chamber and its cannulation both at the left atrium and 
the aorta. Perfusate flows in a retrograde manner from the left atrium, into 
the left ventricle, and then pumped out through the aorta. The coronary 
effluent is collected from perfusate that flows out the coronary arteries 
proximal to where the aorta is cannulated. For orientation purposes, the 
oxygenator (A), perfusion chamber (B), and compliance chamber (C) are 
labeled, as well. 
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H2O and NaHCO3. The mixture was then oxygenated with 95:5% O2:CO2 for 15 minutes 
before CaCl2 was added. In order to determine the effect of glucose on growth signaling 
in the stressed heart, substrates were then added to the buffer to make up the perfusate, 
as indicated in Table 2.2. Both metformin (Sigma Aldrich, St. Louis, MO) and 4-
phenylbutyrate (Calbiochem, San Diego, CA) were dissolved in H2O prior to being 
added to the perfusate. 
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Table 2.2 Ex vivo perfusion protocols used to study glucose activation of mTOR 
signaling at high workload.*note: Four different sets of rats were perfused with 
glucose and subjected to high workload. (1) The first set were untreated prior to 
perfusion. (2) The second set received mTOR inhibitor rapamycin (PO, 4 mg/kg/day) 
for 7 days prior to perfusion (or vehicle control). (3) The third set received metformin 
(IP, 250 mg/kg/day or 500 mg/kg/day) for 7 days prior  to perfusion (or vehicle 
control). (4) The last set  of  hearts were perfused  with either metformin (5 mM, 7.5 
mM, or 10 mM) or  4-phenylbutyrate (PBA, 10 mM) added directly to the buffer.  
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2.3.2.2. Determination of Cardiac Power, Rates of Glucose Uptake and Oxidation 
Determination of Cardiac Power: 
 Cardiac power was used as a marker for contractile function in this project. 
Cardiac power (mW) was calculated as the product of mean arterial pressure, estimated 
as the height of the afterload (in cm H2O) times the cardiac output (sum of the aortic 
output and coronary flow). Aortic output and coronary flows were derived by measuring 
the number of seconds needed to collect 10 mL of perfusate in the aortic and coronary 
overflow reservoirs, respectively, every five minutes throughout each perfusion protocol. 
These measurements were then converted into mL/min by multiplying by a factor of 60.   
Determination of Rates of Glucose Uptake: 
 Rates of glucose uptake (and subsequent phosphorylation) were determined by 
adding 2-[3H]-glucose to the perfusion buffer and measuring the release of [3H]2O in the 
coronary effluent. When glucose is taken up by the cardiomyocyte, it is immediately 
acted upon by hexokinase and converted into glucose 6-phosphate. When glucose 6-
phosphate is then reversibly converted into fructose 6-phosphate by 
phosphoglucoisomerase, [3H]2O is released into the coronary effluent (Katz and Dunn 
1967). The overall reaction is: 
2-[3H] glucose + 2 NAD+ + 2 ADP  2 pyruvate + 2 [3H]2O + 2 NADH + 2 ATP + 2H+  
We collected 2 mL of coronary effluent every 5 minutes in order to assess rates of 
glucose uptake throughout each 60 minute perfusion. A sample of unused perfusate was 
collected at the end of each perfusion for background radioactivity measurements. 
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[3H]2O was separated from unmetabolized 2-[3H] glucose and other [3H] labeled 
compounds by retention and elution in an ion exchange column. Columns were packed 
with glass wool and filled with 1.5 mL of AG1-X8 anion exchange resin (BioRad, 
Hercules, CA). After washing the resin with 6 mL of H2O, aliquots (.5 mL) of sample 
were added and eluted into scintillation vials with 3.5 mL H2O plus 13 mL Ultima Gold 
liquid scintillation cocktail and radioactivity was measured by a Packard scintillation 
counter, as described earlier. Specific activity, the amount of radioactivity of the 
particular radionuclide (SA=tracer (dpm)/tracee (umol)), in the perfusate was 
concurrently measured by adding .5 mL of unused perfusate directly to 13 mL of 
scintillation cocktail.  
Determination of Rates of Glucose Oxidation: 
 Rates of glucose oxidation were determined by adding U-[14C] glucose to the 
perfusion buffer and measuring the release of [14C]O2 in the coronary effluent. [14C]O2 is 
released in the Krebs Cycle when isocitrate (6C) is converted to α-ketoglutarate (5C) by 
isocitrate dehydrogenase and when α-ketoglutarate (5C) is converted to succinyl CoA 
(4C) by α-ketoglutarate dehydrogenase. The overall reaction is: 
U-[14C] glucose  U-[14C] acetyl CoA  [14C]O2 
[14C]O2 release into the coronary effluent is therefore proportional to the rate of glucose 
oxidation under the given perfusion conditions and can be calculated. In each coronary 
effluent sample, [14C]O2 was separated from unmetabolized U-[14C] glucose and other 
[14C] labeled compounds by acidification and CO2 trapping by hyamine hydroxide 
(Goodwin et al JBC 1998). Specifically, 1 mL of Hyamine Hydroxide (Perkin Elmer, 
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Waltham, MA) was added to the bottom of a scintillation vial. An open eppendorf tube 
containing .5 mL of coronary effluent was then placed in the scintillation vial and closed 
with a subaseal rubber bung. 200 mL of 60% perchloric acid (v:v) was then injected into 
each Eppendorf tube to trigger release of [14C]O2 and trapping by hyamine hydroxide. 
Each scintillation vial was stored overnight to allow the reaction to occur to completion. 
13 mL Ultima Gold liquid scintillation cocktail was added the next morning and 
radioactivity was measured by a Packard scintillation counter, as described earlier. 
 
2.3.3. Spectrophotometric enzymatic metabolite analysis 
 Using heart tissue that had been stored at -80oC, approximately 500 mg of 
pulverized frozen heart tissue was added to .5 mL 6% perchloric acid on ice to 
precipitate out proteins and halt all metabolic activity (Wiliamson, Corkey 1967). Tissue 
was then homogenized for roughly 30 seconds with a Polytron® homogenizer. The 
suspension was then neutralized by the addition of KIK (6M KOH, .4M imidazole, .4M 
KCl), vortexed, and centrifuged at 13,000 rpm to isolate out metabolites. Metabolite 
concentrations were then determined by enzymatic spectrophotometric analysis, as 
detailed below. In each instance, absorbance at 340 nm was read in samples placed in 
plastic cuvettes (10 mm light path) before and after addition of enzyme. Incremental 
changes in absorbance with time indicated when each reaction was completed.  
 Metabolite concentrations of glucose 6-phosphate, fructose 6-phosphate, and 
adenosine-5’-triphosphate (ATP) were measured by a spectrophotometric enzymatic 
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analysis using glucose-6-phosphate dehydrogenase coupled to NADPH production with 
extinction at 340 nm.  
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 Similarly, conentrations of adenosine-5’-diphosphate (ADP) and adenosine-5’-
triphosphate (ATP) were measured using lactate dehydrogenase coupled to the oxidation 
of NADH to NAD+ with extinction at 340 nm (Bergmeyer 3rd edition) in a three-step 
reaction. 
 
 
 A colorimetric Bradford assay was completed to determine the total protein 
concentration in each sample (Bradford 1976). Metabolite concentrations were 
normalized to total protein content in each sample.  
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2.3.4. Western Immunoblotting 
Protein Extraction 
 Total protein was extracted from frozen heart tissue by homogenizing 100 mg 
left ventricular tissue at maximum speed for 30 seconds in extraction buffer (30 mM 
Hepes, 2.5 mM EGTA, 2.5 mM EDTA, 20 mM Kcl, 40 mM glycerophosphate, 40 mM 
NaF, 4 mM NaPPi 10% glycerol, .1% non-idet P40) using a Polytron® homogenizer. 
The suspension was then centrifuged for 30 minutes at 13,000 rpm and the supernatant 
(protein) was recovered. A colorimetric Bradford assay was completed to determine the 
protein concentration in each sample (Bradford Anal Biochem. 1976). Aliquots of 25 ug 
were prepared in 2X protein loading buffer (1M Tris HCl, glycerol, 10% SDS, .1% 
Bromophenol Blue, 2-mercaptoethanol) and stored at -80oC.  
 
Western blotting 
 Protein lysates were separated by SDS-PAGE (polyacrylamide gel 
electrophoresis) and transferred onto a nitrocellulose membrane using a Trans-Blot SD 
Semi-Dry Electrophoretic Transfer Cell (BioRad, Hercules, CA). Ponceau staining of the 
membrane was used to confirm uniform transfer of proteins throughout the membrane. 
Membranes were destained with .4% TBS-T (Tris base in NaCl, in .4% tween-20 
detergent) then washed in 5% nonfat milk in TBS-T for two hours at room temperature 
to block non-specific sites on the membrane. Membranes were then incubated at 4oC in 
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primary antibody solution (in 5% BSA in TBS-T) overnight. After unbound primary 
antibody was washed off with TBS-T the next morning and the membrane was incubated 
in horseradish peroxidase (HRP)-conjugated secondary antibody for one hour at room 
temperature. Subsequent addition of a chemiluminescent luminol reagent produced light 
that was captured on film and developed in a dark room. Changes in the phosphorylated 
protein to total protein ratio by Western immunoblotting is uniformly accepted as an 
indicator of protein activation/inactivation along the mTOR signaling cascade and was 
therefore assessed in all hearts.   
 
2.3.5. Quantitative Reverse Transcription Polymerase Chain Reaction (qRTPCR) 
RNA Extraction 
 Total RNA was extracted from frozen heart tissue by first homogenizing 100 mg 
left ventricular tissue at maximum speed for 30 seconds in guanidinium thiocyanate-
phenol-chloroform extraction (Tri-Reagent, MRC, Cincinnati, OH). The suspension then 
underwent phase separation by a series of centrifugation steps. In the final step, RNA 
was precipitated out of the aqueous phase by isopropanol. RNA concentration was then 
measured with a Nanodrop ND-1000 Spectrophotometer. All RNA samples were diluted 
to a final concentration of 30 ng/uL and stored at -80oC. 60 ng of RNA were analyzed in 
triplicate per sample.  
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qRTPCR 
 RNA was first reverse transcribed into its complementary DNA by reverse 
transcriptase (Invitrogen, Carlsbad, CA) and the resulting cDNA was amplified by real-
time PCR using the ABI Prism 7100 SDS. On each 96-well plate, select samples were 
also run in the absence of reverse transcriptase to detect DNA contamination. These 
samples served as the non-amplified control (NAC). Fluorescence is produced by 
cleavage of a reporter dye from a quencher dye on a nucleic acid probe that is degraded 
by Taq polymerase during each cycle of PCR. The number of cycles necessary to reach a 
fluorescence threshold (Ct) is used to determine the amount of RNA transcripts present 
in each sample compared to standard amounts of RNA over a log range of 
concentrations (Fig. 2.3). Data are presented as transcript copy per nanogram of RNA. 
Primer and probe sequences have been previously published (Harmancey, Wilson et al. 
2010) and are listed below: 
 
Glucose Regulated Protein 78 (GRP78) 
Forward 5‟-ACCGTCGTATGTGGCCTTCA-3‟  
Reverse 5‟-TCCGGGTTGGACGTGAGTT-3‟  
Probe 5‟-FAM-CTGATTGGCGATGCGGCC-TAMRA-3‟  
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Glucose Regulated Protein 94 (GRP94) 
Forward 5‟-TGTCAAAGGTGTTGTGGATTCC-3‟  
Reverse 5‟-AGAGTTTTGCGGACAAGCTTCT-3‟  
Probe 5‟-FAM-TCTCCCCCTCAATGTTTCCCGTGA-TAMRA-3‟  
  
Endoplasmic Reticulum Protein 72 (ERp72) 
Forward 5‟-CTTCTAACGATGCTAAGCGGTACA-3‟  
Reverse 5‟-CGCCAAAACTGAGTAGCAGTTCT-3‟  
Probe 5‟-FAM-CAAGCGCCCCCTGGTGGTTGTA-TAMRA-3‟  
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2.3.6  Statistical Analysis 
 Two way repeated measures analysis of variance (ANOVA) and Holm-Sidak 
post hoc test were used to compare cardiac power, rates of glucose uptake, and rates of 
glucose oxidation between different groups of hearts perfused ex vivo. All numerical 
data were displayed as a mean ± SEM. A p<0.05 was considered statistically significant. 
 
 
 
Figure 2.3 Sample Standard Curve Used to Quantify mRNA Transcript levels of 
ER stress markers. The fluorescent signal for up to 40 cycles of PCR are recorded 
from standard amounts of mRNA. A non-amplification control (NAC, sample without 
reverse transcriptase) is run alongside each set of samples.   
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CHAPTER 3: LOAD-INDUCED MTOR ACTIVATION IS MEDIATED BY 
GLUCOSE 6-PHOSPHATE ACCUMULATION 
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3.1 Introduction 
 
 This chapter includes rationale, results, and discussion of the experiments in 
support of the hypothesis that load-induced mTOR activation is mediated by glucose 6-
phosphate accumulation. Hypertension, valvular heart disease, anemia, and prior 
myocardial infarctions all stress the heart with an increase in workload and can 
ultimately lead to heart failure. Metabolically, hearts increase their reliance on glucose 
for energy provision (Goodwin, Taylor et al. 1998) and structurally, hearts hypertrophy 
when stressed (Dorn and Force 2005). However, the mechanisms that trigger a heart to 
hypertrophy and ultimately fail under such conditions remain largely unknown. We 
therefore investigated whether the metabolic remodeling process drives the structural 
and functional remodeling process in hearts subjected to high workload via mTOR 
activation.  
 Load-induced cardiac hypertrophy is largely driven by the mammalian target of 
rapamycin (mTOR), a major regulator of protein synthesis that is located dowstream of 
the PI3K-Akt signaling pathway (Fig. 3.1). mTORC1 directly triggers cardiac 
hypertrophy via activation of p70S6 kinase (p70S6k) and 4E-binding protein 1 (4EBP1), 
which promote ribosomal biogenesis and CAP-dependent protein translation, 
respectively. 
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Figure 3.1 Proposed activation of the mTOR signaling pathway by glucose. Load-
induced mTOR activation is known to occur via the PI3K-Akt signaling pathway. 
Whether the heart’s increased reliance upon glucose at high workload regulates this 
signaling pathway is unknown. 
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 mTORC1 plays a critical role in promoting cardiac growth in response to 
increased workload (Shioi, McMullen et al. 2003). mTOR also couples energy and 
nutrient abundance to cell growth owing ot the capacity to sense nutrients, stress, and 
growth factors (Zoncu, Efeyan et al. 2011). It is also known to be activated by nutrients 
and growth factors (Proud 2002). Whether load-induced mTORC1 activation in the heart 
is regulated by physiological changes in energy substrate metabolism in the stressed 
heart was unknown at the beginning of my project. We previously reported that the 
insulin signaling pathway and mTORC1 can only be activated by the combination of 
glucose and insulin in rat heart (Sharma, Guthrie et al. 2007).  I extended this work and 
investigated the metabolic, functional and structural consequences of glucose-mediated 
mTOR signaling in the stressed heart.   
 The chapter addresses the following four objectives: 1) Determining whether in 
hearts subjected to increased workload in vivo, metabolic remodeling precedes the 
structural and functional remodeling process. 2) Determining whether load-induced 
mTOR activation is dependent upon the heart’s increased reliance upon glucose at high 
workload. 3) Elucidating the mechanism by which changes in glucose metabolism 
modulate phosphorylation (i.e. activation) of proteins along the PI3K/Akt and 
TSC2/mTOR axis at high workload. 4) Identifying the functional consequences of 
sustained mTOR activation and determining whether these consequences are 
preventable.  
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 We investigated whether signals generated by glucose metabolism regulate 
mTOR activation in the heart when it is subjected to high workload. I tested this 
hypothesis by first subjecting mice to increased workload in vivo and serially monitoring 
changes in glucose metabolism, contractile function, and structure using PET and MRI 
imaging. I then assessed mTOR activation in these hearts to determine whether the 
metabolic or structural changes were associated with changes in mTOR activation. Next, 
to determine the mechanism by which changes in glucose metabolism regulate mTOR 
activation in vivo, I systematically modulated substrate supply and workload to the heart 
ex vivo and assessed changes in the activation of nearly every major protein involved in 
the mTOR signaling cascade. Lastly, I investigated whether or not markers of load-
induced mTOR activation were metabolically regulated in left ventricular tissue from 
failing human hearts before and after implantation of an LVAD. My objective was to 
establish that pathways of protein synthesis are metabolially regulated in the heart and to 
determine whether any of the findings in animal models are also present in th failing 
human heart. It was my expectation that these results provide evidence to support the 
idea that modulation of cardiac metabolism can be used to regulate cardiac growth and 
contractile function. 
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3.2  Results 
 
3.2.1. Metabolic Remodeling Accompanies Functional but Precedes Structural 
Remodeling In Response to Increased Workload In Vivo 
 
 In order to determine whether enhanced glucose uptake precedes the structural 
and functional remodeling process in response to increased cardiac workload in vivo, 
mice were serially imaged with FDG-PET and MRI 1 day, 2 weeks, and 4 weeks to 
transverse aortic constriction (TAC) in the laboratory of our collaborator Bijoy Kundu at 
the University of Virginia. Transverse end-diastolic FDG-PET images demonstrated a 5-
fold increase in the rate of myocardial FDG uptake beginning 1 day after TAC, which 
further increased (1.5- to 3.2-fold) over 4 weeks (Fig. 3.2A-B). Sham operated animals 
showed no change in FDG uptake over the same period. The PET images also suggested 
hypertrophy and an enlargement in LV cavity in the TAC mice, but only at 2 and 4 
weeks. 
 While metabolic remodeling was detected 1 day after TAC, no structural changes 
were appreciated at this early time point by MRI. There was no significant increase in 
either the heart weight to body weight ratio (HW/BW) (Fig. 3.2C) or end diastolic wall 
thickness (Fig. 3.2D) 1 day after TAC. Both HW/BW and end diastolic wall thickness 
exhibited a 1.4 fold increase only after 2 and 4 weeks after TAC. There was no 
significant change in HW/BW or wall thickness over 4 weeks in sham-operated mice.  
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 In order to determine whether functional changes accompanied the early 
metabolic or later structural changes in response to high workload, end-diastolic volume 
(EDV), end-systolic volume (ESV) and ejection fraction (EF) were also assessed by 
Figure 3.2 Metabolic remodeling precedes structural remodeling in hearts 
subjected to high workload in vivo. (A) 1 day after TAC, there is an increase in 
FDG uptake prior to any structural changes in the heart. (B) Myocardial FDG uptake 
(Ki) in TAC mice demonstrates a 5-fold increase in FDG uptake at day 1, and a 1.5- 
to 3.2-fold increase from day 1 to 4 weeks. Sham operated mice show no significant 
change in FDG uptake over 4 weeks. (C) Body weight (BW) was recorded and heart 
weight (HW) was measured using MRI in vivo. HW/BW remains unchanged 1 day 
after TAC, but increases 1.4- and 1.7-fold between day 1 and 4 weeks, respectively. 
HW/BW shows no significant change over 4 weeks in sham operated mice. (D) End 
diastolic wall thickness is unchanged 1 day after TAC, but increases about 1.4-fold 
between day 1 and 4 weeks. Wall thickness shows no significant change over 4 
weeks in sham operated mice.  n=8 for the TAC and n=5 for the shams. All values are 
mean ± SD. #p<0.05 day 1 vs BSL, *p<0.001 vs BSL, day 1, 2 weeks, **p<0.05 vs 
BSL, day 1; ^p<0.05 between the TAC and sham groups on the same day. Imaging 
studies and analysis were completed at our collaborator Bijoy Kundu’s laboratory at 
The University of Virginia Medical School.  
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MRI. There were no significant changes in EDV at 1 day after TAC (Fig. 3.3A), but 
there were increases in ESV (Fig. 3.3B) and significant decreases in EF (Fig. 3.3C) at 
the same time point. Both ESV and EDV (Fig. 3.3A-B) progressively increased 2 and 4 
weeks after TAC, while the EF progressively declined over the same time period. There 
were no significant changes in EDV, ESV, or EF in sham operated animals over 4 
weeks. Collectively, the data support the hypothesis that metabolic changes precede 
structural changes and accompany functional changes in hearts subjected to increased 
workload in vivo.  
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3.2.2. My central hypothesis: Load-Induced mTOR Activation Requires Glucose 
 
 Because metabolic changes occur instantaneously in response to increased 
workload in vivo (as seen above already 1 day after TAC), it was difficult to distinguish 
whether the ‘load-induced’ changes in contractile function and mTOR activation were in 
fact metabolically regulated or not. At this point, it remained a distinct possibility that 
the heart’s observed increased reliance upon glucose in vivo occurred simultaneously, 
but independently, to the changes in cardiac growth. In order to determine whether load-
induced mTOR activation and contractile dysfunction is regulated by glucose 
Figure 3.3 Functional changes accompany metabolic changes in response to high 
workload. (A) End-systolic volume (ESV), (B) end-diastolic volume (EDV), and 
resultant  (C) ejection fractions (EF) were assessed in vivo using MRI. An increase in 
ESV and decline in EF is present 1 day after TAC. Sham operated mice exhibited no 
significant change in EDV, ESV and EF over 4 weeks. n=8 for TAC group and n=5 
for the shams. All data are mean ± SD. In the plot for ESV, *p<0.005 vs BSL and 1d; 
**p<0.05 vs BSL and 1d. In the plot for EDV, *p<0.01 vs BSL and 1d. In the EF 
plot, *p<0.05 vs 1 d, 2 wks and 4 weeks; ^p<0.05 between the TAC and sham groups 
on the same day.  Data are from Dr. Kundu’s lab at The University of Virginia.  
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metabolism, cardiac substrate supply and workload were independently modulated ex 
vivo. I performed four sets of matched perfusions: (1) at normal workload (near-
physiologic) with acetoacetate plus propionate (control with only non-carbohydrate 
substrates, NCS) (2) at increased workload (high physiologic) with NCS (control) (3) at 
normal workload with glucose (at physiologic 5 mM concentration) as the only substrate 
(4) at increased workload with glucose (5 mM) as the only substrate. A second set of rats 
were pretreated with mTOR inhibitor rapamycin (PO, 4 mg/kg/day) or vehicle control 
(propylene glycol) 7 days prior to sacrifice. The hearts were subjected to the same 
protocols to assess whether changes in cardiac power were in fact due to changes in 
mTOR activation or not. Cardiac power was assessed and the hearts were freeze-
clamped at the end of the perfusion protocol at 60 minutes. 
 We determined that increased workload (depicted as orange) triggers 
phosphorylation of upstream PI3K and Akt in all rat hearts irrespective of substrate 
supply. However, increased workload alone is not sufficient to activate TSC2, mTOR, or 
its downstream targets. Maximal TSC2, mTOR, p70S6K, and 4EBP1 phosphorylation 
occurs only in hearts perfused with glucose and subjected to increased workload (Figure 
3.4).  
 Others in the lab had previously demonstrated that 7 day rapamycin pretreatment 
prior to perfusion effectively inhibits mTOR in the isolated working rat heart (Sharma, 
Guthrie et al. 2007). I now elucidated its effect on the entire mTOR signaling pathway. 
Rapamcyin pretreatment did not effect PI3K phosphorylation, but inhibited 
phosphorylation of Akt, TSC2, mTOR, p70S6K, and 4EBP1 in hearts subjected to 
increased workload with glucose. Not surprisingly, the mTOR signaling cascade was not 
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activated in hearts perfused at normal, physiological workload in the presence or absence 
of glucose (blue). 
 
 
Figure 3.4 In hearts subjected to high workload, glucose activates mTOR. 
The mTOR signaling pathway was assessed by western blot in isolated 
working rat hearts perfused as described in Table 2.2. Increased 
phosphorylation of upstream PI3K and AKT were seen in all hearts perfused 
at high workload. Increased phosphorylation of TSC2, mTOR and p70S6K 
required glucose at high workload. Rapamycin administration for 7 days (4 
mg/kg/day) prior to perfusion inhibited phosphorylation of Akt, TSC2, 
mTOR, and its downstream targets. The perfusion medium contained no 
insulin. NCS refers to noncarbohydrate substrates (acetoacetate, 7.5 mM and 
propionate, 5 mM); Glucose refers to hearts perfused with only glucose (5 
mM).   
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 Next I wanted to demonstrate that hearts perfused ex vivo with physiological 
concentrations of glucose, fatty acids, acetoacetate, and propionate (mixed) would 
demonstrate these same properties, we also assessed the phosphorylation of P70S6K and 
4EBP1 in hearts perfused with mixed substrates at normal and high workload. Like 
hearts perfused with glucose alone, hearts perfused with mixed substrates demonstrated 
increased phosphorylation of P70S6K and 4EBP1 at high workload (Fig 3.5). This 
suggested that amongst the substrates that perfuse the heart, glucose alone is sufficient 
for mTOR activation at high workload. 
  
Figure 3.5 In the presence of mixed substrates, mTOR signaling is activated and 
G6P levels are elevated at high workload. P70S6K and 4EBP1 phosphorylation were 
increased to the same extent in hearts perfused at high workload with mixed substrates 
compared to hearts perfused with glucose alone. Data are shown as mean ± SEM, n=5-8. 
See text and earlier figures for definition of terms. Mixed refers to hearts perfused with a 
mixture of substrates at physiologic concentrations (glucose at 5 mM, oleate at .4 mM, 
acetoacetate at 7.5 mM, and propionate at 5 mM). 
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3.2.3. mTOR Activation Impairs Contractile Function At High Workload 
 
 To determine the functional consequence of glucose-mediated mTOR activation, 
we calculated cardiac power in all perfused hearts (Figure 3.6). Under all conditions, 
cardiac power was stable both at normal workload and at increased workload, 
representing the stability of the model. At normal workload, there was no significant 
difference in cardiac power between hearts perfused with glucose (11.89± 1.3 mW) and 
hearts perfused with NCS (12.12± 0.83 mW). However, when subjected to increased 
workload ex vivo, hearts perfused with glucose (16.37± 1.5 mW) displayed in a 29% 
decrease in cardiac power compared to hearts perfused with NCS (18.91± 0.84 mW). 
Rapamycin pretreatment for 7 days prior to perfusion prevented the decline in contractile 
function in hearts perfused with glucose at increased workload (20.75± 1.32 mW), 
suggesting that the decreased cardiac output in hearts perfused with glucose at high 
workload is mTOR-dependent. The mechanism for this phenomenon is unknown but 
may relate to the unfolded protein response (see next chapter). Rapamycin had no 
significant effect on cardiac power in hearts perfused with NCS or in hearts perfused at 
normal (near-physiological) workload (not shown for clarity).  
 
 
 
 
69 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 In hearts subjected to high workload, cardiac power is impaired 
when glucose is the only substrate. Rapamycin rescues contractile function. 
Cardiac power was assessed every 5 minutes throughout each 60 minute 
perfusion. At normal workload, neither glucose nor rapamycin had an effect on 
cardiac power. At increased workload, glucose impaired cardiac power. 
Rapamycin improved contractile function in stressed hearts perfused with 
glucose. Rapamycin did not change contractile function in hearts perfused with 
NCS (data not shown for clarity). Data are shown as mean ± SEM, n=5-8, 
*p<0.002 compared to hearts perfused with NCS + vehicle and glucose + 
rapamycin at high workload.  
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3.2.4 High Workload Induces A Mismatch Between Rates Of Glucose Uptake 
And Oxidation 
 
 To elucidate the mechanism of glucose-mediated mTOR activation, I assessed 
rates of glucose uptake and oxidation under all conditions. In vehicle treated rats, rates 
of glucose uptake (4.2 ± 0.7 µmoles/min/g dry wt) matched rates of glucose oxidation 
(3.9 ± 0.7 µmoles/min/g dry wt) at normal workload. When subjected to increased 
workload, rates of glucose uptake (11.5± 0.8 µmoles/min/g dry wt) exceeded rates of 
glucose oxidation (9.5± 0.6 µmoles/min/g dry wt). Pretreatment with the mTOR 
inhibitor rapamcyin (4 mg/kg/d) for 7 days prevented this mismatch between glucose 
uptake and oxidation. Pretreatment of rats with rapamycin reduced rates of glucose 
uptake (4.4± 0.7 µmoles/min/g dry wt) and glucose oxidation (4.3± 0.7 µmoles/min/g 
dry wt) when hearts were subjected to increased workload (Fig. 3.7). This observation 
suggests the following – there is an increase in cardiac efficiency when animals are pre-
treated with rapamycin, and the metabolic stress of glucose in the hearts from untreated 
animals leads to proteotoxicity (discussed below).  
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Figure 3.7 Rates of glucose uptake exceed rates of glucose oxidation in 
response to high workload. Rapamycin corrects this mismatch. Rates of 
glucose uptake and oxidation were closely coupled at normal workload (in both 
vehicle and rapamycin treated rats). At high workload, rates of glucose uptake 
exceeded rates of glucose oxidation in vehicle treated rats. Rapamycin treatment 
significantly reduced rates of both glucose uptake and oxidation. * p<0.05 versus 
rates of glucose uptake in vehicle treated rats. #p<.001 versus metabolic rates in 
vehicle treated rats. 
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3.2.5.  Glucose 6-Phosphate Accumulates At High Workload as a Consequence of a 
Mismatch between Rates of Glucose Uptake and Oxidation 
 
 Because mTOR activation was associated with a mismatch between glucose 
uptake and oxidation, we investigated whether the accumulation of glucose or one of its 
metabolites correlated with mTOR activation. Levels of glucose 6-phosphate (G6P) 
directly correlated with mTOR activation (Fig. 3.7-3.8). G6P levels were 4.3-fold higher 
in hearts subjected to an acute increase in workload (4.4± 1.0 nmoles/mg protein) 
compared to hearts perfused at physiologic workload (1.0± 0.5 nmoles/mg protein). 
Rapamycin pretreatment blunted G6P levels (0.36± 0.1 nmoles/mg protein) in hearts 
perfused at increased workload. In contrast, levels of other upstream glycolytic 
intermediates were unchanged at high workload.  
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Figure 3.8 G6P accumulates in response to high workload. Cardiac G6P levels 
were assessed in freeze-clamped hearts. Subjecting hearts to high workload ex 
vivo induced a 4-fold increase in G6P levels, which was reversed with rapamycin 
treatment. Rapamycin = hearts from animals pretreated with rapamycin for 7 
days. See text for further detail.   
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3.2.6.  Accumulation Of Glucose 6-Phosphate Analogue 2-Deoxy-Glucose 6-
Phosphate Activates mTOR 
 
 To verify whether G6P accumulation was a cause or consequence of mTOR 
activation in hearts subjected to increased workload, I perfused hearts with the following 
glucose analogues: (1) 3-O-methylglucose (which is taken up by the cardiomyocyte but 
not metabolized) and (2) 2-deoxyglucose (which is taken up by the cardiomyocyte, 
phosphorylated and trapped as a G6P analogue) (Fig. 3.9). Following perfusion, Akt, 
TSC2, mTOR and p70S6K phosphorylation were assessed in freeze-clamped hearts. At 
high workload, increased AKT phosphorylation was present when hearts were perfused 
with both 3-O-methylglucose and 2 DG. However, 3-O-methylglucose was unable to 
increase phosphorylation of TSC2, mTOR or its downstream target p70S6K in hearts 
perfused at high workload. However, 2-deoxyglucose phosphorylated TSC2, mTOR and 
p70s6k to an even greater extent then in hearts perfused with glucose at high workload. 
mTOR and p70S6K were not phosphorylated in hearts perfused with either glucose 
analogue at normal workload. Hexose 6-phosphate levels were assessed by enzymatic 
spectrophotometric analysis and demonstrated that a correlation with mTOR activation 
in hearts perfused with non-metabolizable glucose analogues, as well (Fig. 3.10). These 
experiments provide further evidence that G6P is associated with mTORC1 activation in 
hearts subjected to increased workload.  
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Figure 3.9 Glucose analogues used in isolated working heart perfusions. Hearts were 
perfused ex vivo for either 60 minutes under normal workload (pink) or for 30 minutes 
under normal workload and subsequently for 30 minutes at high workload (red). Hearts 
were perfused with either glucose, 2-deoxyglucose (which is phosphorylated by 
hexokinase and retained in the cardiomyocyte as the G6P analogue, 2-DG 6-P), or 3-O-
methylglucose (which cannot be acted upon by hexokinase and remains in the 
cardiomyocyte as a free glucose analogue). All hearts perfused with glucose analogues 
were also perfused with acetoacetate (7.5 mM) and propionate (5 mM) for energy 
provision.  
Figure 3.10 Increased phosphorylation of mTOR and p70S6K is associated with 
increased hexose 6-phosphate levels in hearts perfused with 2DG. Representative western 
blots of Akt, TSC2, mTOR and p70S6K phosphorylation in hearts perfused with glucose and 
glucose analogues 2 deoxyglucose (2DG) and 3-O-methylglucose (3OMG) at either normal 
or high workload. 2DG, but not 3OMG, increased phosphorylation of TSC2, mTOR, and 
p70S6K at high workload. Hearts perfused with 2DG had significantly increased levels of 
intracardiac hexose 6-phosphate levels. All hearts perfused with glucose analogues were also 
perfused with acetoacetate (7.5 mM) and propionate (5 mM) for energy provision. 
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3.2.7. Glucose 6-Phosphate-dependent mTOR Activation is Mediated By 
Downregulation of AMPK 
 
 Up to this point my data suggest that TSC2 or one of its upstream regulators 
mediates G6P-dependent mTOR activation in the heart. AMPK is a heterotrimeric 
enzyme that lies upstream of TSC2 and regulates fuel supply and substrate metabolism 
in response to the metabolic milieu of the heart. When phosphorylated at Thr 172, 
AMPK phosphorylates acetyl co-A carboxylase (ACC) at Ser 79, a commonly used 
marker of AMPK activation, and phosphorylates TSC2 at Ser1387 and RAPTOR at Ser 
792 to inhibit mTOR (Young, Cell Metabolism 2008). High glucose-mediated mTOR 
activation is regulated by a downregulation in AMPK in skeletal muscle (Saha et al. 
Diabetes 2010). I therefore examined changes in AMPK phosphorylation in all perfused 
hearts. Neither increased workload nor glucose alone was associated with a change in 
AMPK phosphorylation. However, perfusion at increased workload with glucose led to a 
downregulation of phospho-AMPK (Thr 172), phospho-ACC (Ser 79) and phospho-
TSC2 (Ser 1387). Rapamycin treatment prevented the downregulation of AMPK, ACC, 
and TSC2 phosphorylation. RAPTOR phosphorylation was unchanged with workload or 
rapamycin treatment (Fig. 3.11). 
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Figure 3.11 G6P-dependent mTOR activation is mediated by AMPK 
downregulation. (A) Representative western blots demonstrate a reduction in AMPK 
phosphorylation (T 172) and ACC phosphorylation (Ser 79) in hearts perfused with 
glucose at high workload.  
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3.2.8 Metformin Inhibits mTOR Activation and Rescues Contractile Function at 
High Workload 
 To confirm whether AMPK downregulation was necessary for glucose-
dependent mTOR activation and to determine whether it could be prevented with 
metformin (AMPK activator) pretreatment, rats were systemically pre-treated with either 
control (NaCl) or metformin in vivo for 7 days (IP, 250 mg/kg/d or 500 mg/kg/d) prior to 
being perfused with glucose at high workload. Compared to control treatment, 
metformin prevented AMPK downregulation and inhibited mTOR, p70S6K, and 4EBP1 
phosphorylation in a dose-dependent manner (Fig. 3.12). In order to determine whether 
these effects were due to metformin’s systemic effects or direct effects in the heart, I 
perfused hearts with glucose at high workload in buffer that contained metformin at 
three doses (5 mM, 7.5 mM, 10 mM). Ex vivo perfusion with metformin also prevented 
AMPK downregulation and inhibited mTOR, p70S6K, and 4EBP1 phosphorylation in a 
dose-dependent manner in hearts perfused at high workload with glucose (Fig. 3.12). 
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 We assessed rates of glucose uptake and oxidation as well as cardiac glucose 6-
phosphate levels in these hearts, as well. In unstressed hearts (perfused at normal 
physiologic workload), systemic in vivo metformin treatment did not significantly 
change rates of glucose uptake or glucose oxidation. In hearts subjected to high 
workload, in vivo metformin treatment did not change rates of glucose uptake (11.7± 1.1 
µmoles/min/g dry) but increased rates of glucose oxidation (11.0± 0.7 µmoles/min/g 
dry) and blunted G6P accumulation compared to vehicle treated animals (Fig 3.13). 
Metformin improved cardiac power 26% in hearts perfused at increased workload with 
glucose (Fig. 3.14). Metformin treatment had no effect on mTOR phosphorylation or 
cardiac power in hearts perfused at physiologic workload.  
Figure 3.12 G6P-dependent mTOR activation is inhibited by metformin. Both in 
vivo metformin prior to perfusion and ex vivo metformin during perfusion increased 
AMPK phoshphorylation and prevented P70S6K phosphorylation in a dose-
dependent manner. 
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 The major regulator of AMPK is a shift in the AMP:ATP ratio. Therefore, I also 
assessed AMP, ADP, and AMP levels in all perfused hearts. Surprisingly, I found no 
significant change in their levels under any perfusion condition (Table 3.1). 
 
 
 
 
 
  
Figure 3.13 Metformin treatment corrects the mismatch between rates of 
glucose uptake and oxidation at high workload and blunuts G6P accumulation. 
Rates of glucose uptake and oxidation were closely coupled at normal workload (in 
both vehicle and metformin treated rats). At high workload (stressed), metformin 
corrected the mismatch between rates of glucose uptake and oxidation (top). G6P 
accumulation was reduced in hearts perfused at high workload with glucose after 
metformin treatment (bottom). * p<0.05 versus rates of glucose uptake in vehicle 
treated rats. #p<.001 versus metabolic rates in vehicle treated rats. 
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Figure 3.14 Metformin treatment improves cardiac power at high workload. 
Contractile performance in the isolated working rat heart perfused with glucose in the 
presence and absence of metformin treatment. n=5-8; *p<0.05  
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3.2.9 Glucose Phosphorylation Modulates mTOR Activation in vivo (TAC and 
ACSL-/- mice)  
 
 To determine whether changes in glucose metabolism led to G6P accumulation 
in mouse hearts subjected to increased workload in vivo, I assessed cardiac G6P 
accumulation and mTOR activation in mice that were sacrificed one day and two weeks 
after transverse aortic constriction (TAC). We selected hearts at one day (before 
significant structural and functional changes) and two weeks (after significant structural 
and functional changes) after TAC in order to check the validity of our hypothesis that 
metabolic changes precede, trigger, and sustain structural and functional changes in 
hearts subjected to increased workload in vivo. Cardiac G6P levels are 2.3-fold and 4.6-
fold higher compared to sham-operated animals 1 day and 2 weeks after TAC, 
respectively (Fig. 3.15). Both P70S6K and 4EBP1 phosphorylation were significantly 
increased both 1 day and 2 weeks after TAC compared to sham-operated mice (Fig 
3.16). 
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Figure 3.15 Early metabolic changes are associated with G6P accumulation in hearts 
subjected to high workload in vivo. Intracardiac G6P levels are 2.3-fold and 4.6-fold 
higher compared to sham-operated animals 1 day and 2 weeks after TAC, respectively. 
n=5-8; *p<0.05  
Figure 3.16 Early metabolic changes are associated with mTOR activation in hearts 
subjected to high workload in vivo. Representative western blots demonstrate an increase 
in p70S6K and 4EBP1 phosphorylation 1 day and 2 weeks after TAC. n=8 for the TAC and 
n=5 for the sham operated mice. *p<.002  
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 Next, I tested my hypothesis in a genetic model that was metabolically similar to 
the pressure overload-induced hypertrophied heart by using the cardiac specific long-
chain acyl coenzyme A synthetase (ACSL) -/- mouse. ACSL is necessary to activate 
fatty acids to their acyl coenzyme A counterparts before they can be oxidized. 
Accordingly, mice hearts lacking ACSL have marked reductions in fatty acid oxidation 
and rely primarily on carbohydrate metabolism for energy provision (Ellis, Mentock et 
al. 2011). As already observed in the ex vivo hearts subjected to increased workload, 
hearts from ACSL -/- mice demonstrate a downregulation of AMPK and an activation of 
mTOR in the absence of any increased mechanical load placed on the heart (Ellis, 
Mentock et al. 2011).  Moreover, the changes in AMPK signaling are independent of any 
change in the AMP/ATP ratio, as well. We assessed G6P accumulation in these mouse 
hearts and demonstrated that G6P accumulation was associated with mTOR activation in 
this mouse model, as well (Fig 3.17). 
 
 
 
Figure 3.17 G6P accumulation correlates with mTOR activation in the ACSL -/- 
mouse. Intracardiac G6P levels are 2.5-fold higher in ACSL -/- mice compared to WT 
mice. N=5. Data are presented as mean ± SEM. 
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3.2.10 Mechanically unloading failing human hearts with a left ventricular assist 
device (LVAD) reduces Glucose 6-Phosphate levels and mTOR Activation  
 
 When the human heart is subjected to sustained increases in workload it 
ultimately fails. Changes in substrate energy have been observed in failing human hearts 
metabolism (Razeghi, Young et al. 2001; Kato, Niizuma et al. 2010), but the effect of 
mechanical unloading on intermediary glucose metabolism and mTOR signaling is not 
known. In order to gain insight into whether ‘load-induced’ cardiac growth is governed 
by G6P accumulation in the failing human heart, I obtained cardiac tissue from Dr. O.H. 
Frazier and his team at the Texas Heart Institute during LVAD implantation and again 
during explantation from 11 non-diabetic patients with idiopathic dilated 
cardiomyopathy and assessed the tissue for changes in G6P concentration and mTOR 
activation. G6P levels significantly decreased after mechanical unloading (Fig. 3.18A-B) 
as did phosphorylation of p70S6K and 4EBP1 (Fig. 3.18C). 
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Figure 3.18 Mechanical Unloading of Failing Human Hearts Reduces G6P 
accumulation and mTOR activation. (A) Intracardiac G6P levels in each patient with 
idiopathic dilated cardiomyopathy before after mechanical unloading. (B) Average G6P 
levels demonstrate a dramatic reduction at time of explant from LVAD. (C) 
Representative western blots demonstrate a reduction in mTOR downstream targets 
P70S6K and 4EBP1 in failing human hearts after mechanical unloading. n=11 paired 
samples. Panel A traces individual patients. Panel B shows mean ± SEM* p< 0.05   
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3.3 Discussion 
 
 Hemodynamic stress induces instant quantitative and qualitative changes in the 
use of energy providing substrates (Goodwin, Taylor et al. 1998). The structural and 
functional response to increased workload has been extensively studied in the murine 
transverse aortic constriction (TAC) model (Rockman, Ross et al. 1991). How the 
metabolic response to increased workload regulates these changes has previously not 
been investigated. 
 I interrogated the consequences of these early metabolic changes and 
demonstrated that signals generated by glucose metabolism are associated with mTOR 
activation and impaired contractile function. The main findings are: 1) In hearts 
subjected to increased workload in vivo, metabolic remodeling precedes structural 
remodeling of the heart and accompanies load-induced mTOR activation and contractile 
dysfunction. 2) Doubling the workload ex vivo increases rates of myocardial glucose 
uptake beyond the heart’s oxidative capacity, resulting in G6P accumulation, which 
mediates load-induced mTOR activation. 4) Correcting the mismatch between glucose 
uptake and oxidation in the stressed heart with mTOR inhibitor rapamcyin or AMPK 
activator metformin prevents G6P accumulation and rescues contractile function in 
hearts subjected to increased workload. 5) In the failing human heart, mechanical 
unloading decreases levels of G6P as well as phosphorylation of p70S6K and 4EBP1. 
This makes it likely that G6P induced changes in mTOR activation and ER stress are of 
clinical relevance for the failing human heart. 
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  While the normal heart primarily oxidizes fatty acids (Bing, Siegel et al. 1954), 
increased energy requirements of hearts subjected to high workload are met by the 
oxidation of carbohydrates (Goodwin, Taylor et al. 1998). The classic explanation for 
this phenomenon is based on the fact that the heart oxidizes the most efficient substrate 
for a given situation (Taegtmeyer, Hems et al. 1980). Specifically, it can be reasoned 
that at a high workload the heart would prefer to utilize glucose since it generates more 
moles of ATP per O2 consumed compared to fatty acids (Korvald, Elvenes et al. 2000).  
I asked myself the question: what if changes in substrate utilization regulate more than 
just energy provision? 
 It is already known that aside from merely providing energy for cell function, 
glucose metabolites regulate gene expression in the liver and pancreatic β-cell (Girard, 
Ferre et al. 1997; Schuit, Huypens et al. 2001) and that long-chain fatty acids are ligand 
activators of PPARα in the heart (Finck and Kelly 2007). The lab initially had asked the 
question: could glucose-driven metabolic gene expression also occur in the heart? 
Previous work demonstrated that changes in glucose metabolism are linked to 
transcriptional changes in gene expression in the heart (Young, Yan et al. 2007). More 
specifically, we recently suggested that the metabolite G6P mediates activation of 
transcription factor carbohydrate responsive binding protein (Li, Chen et al. 2010). This 
work was conducted in parallel with our studies showing that glucose metabolism is 
required for insulin-dependent mTOR activation in the heart (Sharma, Guthrie et al. 
2007). I now provide new evidence that load-induced mTOR activation and contractile 
dysfunction is mediated by G6P, as well. 
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 My mechanistic studies ex vivo stemmed from our observations made in mice 
subjected to an increase in workload in vivo. Compared to hearts from sham-operated 
mice, hearts from banded mice demonstrated enhanced glucose uptake, G6P 
accumulation, mTOR activation and contractile dysfunction one day after TAC prior to 
the presence of structural changes. When increased workload was sustained via TAC for 
up to 4 weeks, increasing cardiac hypertrophy (assessed by our collaborators with 
cardiac MRI and confirmed by us with HW/BW measurements) directly correlated with 
continued increases in FDG retention and G6P accumulation, which suggested that 
metabolic remodeling precedes and potentially triggers and sustains structural 
remodeling of the heart.  
 Previous studies have largely ignored whether cardiac substrate metabolism can 
regulate ‘load-induced’ hypertrophy and contractile dysfunction (Shioi, McMullen et al. 
2003; McMullen, Sherwood et al. 2004; Zhang, Contu et al. 2010). In order to address 
this issue I utilized the isolated working heart model. The isolated working rat heart 
allows a dynamic minute-by-minute assessment of metabolism and function and permits 
us to assess intracellular metabolite concentrations and activation of the major regulatory 
proteins along the mTOR signaling cascade at the end of the perfusion. The ex vivo 
isolated working heart model also provided us complete control over workload, substrate 
concentration and hormone supply. My findings ex vivo demonstrated that an acute 
increase in workload alone is not sufficient to activate mTOR in the absence of glucose. 
Only in the presence of glucose did hearts subjected to high workload demonstrate 
increased phosphorylation of mTOR and its downstream targets p70S6K and 4EBP1, 
suggesting that ‘load-induced’ hypertrophic signaling through mTORC1 is in fact 
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substrate-dependent. More specifically, our data suggested mTORC1 is activated by the 
metabolic signal G6P, which accumulates at increased workload when rates of glucose 
uptake exceed the heart’s oxidative capacity. 
 TSC is the primary critical signaling node upstream of mTORC1 regulated by 
differential phosphorylation on numerous TSC2 serine and threonine residues (Huang 
and Manning 2008). I dissected the load and substrate-dependence of mTORC1 
signaling in the heart and determined that increased workload alone triggers PI3K, Akt, 
and minimal Akt-dependent phosphorylation of TSC2 at Ser939  phosphorylation, both 
in the presence and absence of glucose. However, complete load-induced mTORC1 
activation required not only Akt-dependent phosphorylation of TSC2 at Ser939 but also 
a downregulation of AMPK-dependent phosphorylation of TSC2 at Ser1387 (Shaw, 
Bardeesy et al. 2004), which occured with G6P accumulation. Indeed, AMPK activation 
with metformin, both in vivo and ex vivo, prevented G6P-mediated mTOR activation at 
increased workload in a dose-dependent manner.  
 In skeletal muscle, high levels of glucose activate mTOR in an AMPK-dependent 
manner by modulating redox state (Saha, Xu et al. 2010). In the heart, the redox state 
does not change with workload (Taegtmeyer 1985). Indeed, lactate levels and lactate-to-
pyruvate ratio were unchanged in hearts perfused with glucose at high workload 
indicating no significant changes in the cytosolic state, and presumably, the nuclear 
redox state (NAD+-to-NADH ratio). However, like in skeletal muscle, AMPK 
downregulation by glucose in the heart occurs independent of the energy state, which is 
consistent with previous work that has demonstrated no change in the energy charge of 
the heart with increased workload both ex vivo (Taegtmeyer 1985) (Neely, Denton et al. 
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1972) and in vivo (Balaban, Kantor et al. 1986). AMPK is activated by the AMP/ATP 
ratio in the heart (Young, Li et al. 2005). However, studies have also suggested that 
metabolites such as long-chain fatty acids can activate AMPK without accompanying 
changes in AMP and ATP levels in skeletal muscle (Clark, Carling et al. 2004). 
 In the genetically modified ACSL -/- mouse, which preferentially upregulates 
cardiac glucose metabolism (like a heart subjected to increased workload), G6P levels 
are elevated, AMPK is downregulated, mTOR signaling is activated, and hearts 
hypertrophy independent of change in the AMP/ATP ratio, as well (Ellis, Mentock et al. 
2011). Taken together, our studies highlight that ‘load-induced’ mTOR activation is 
mediated by changes in glucose metabolism. 
 The two major isoforms of transporters that shuttle glucose into the 
cardiomyocyte are GLUT1 (glucose transporter responsible for basal glucose transport 
independent of insulin) and GLUT4 (glucose transporter responsible for insulin-
mediated glucose transport into the cardiomyocyte). Interestingly, hearts overexpressing 
GLUT1 hypertrophy (Liao, Jain et al. 2002) as do hearts deficient in GLUT4 likely 
secondary to compensatory GLUT1 overexpression (Abel, Kaulbach et al. 1999). These 
data support our hypothesis that non-insulin mediated glucose uptake likely plays a 
major role in mediating cardiac growth. Glucose uptake is increased in both models, 
which gives indirect support to my hypothesis. Neither group assessed the role of 
intermediary metabolite accumulation or mTOR activation in their models.  
 Enhanced glucose uptake in the heart has been associated with contractile 
dysfunction and deemed ‘glucotoxic’ by increasing flux through the hexosamine 
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biosynthetic pathway, dysregulating protein glycosylation, and producing reactive 
oxygen species (Ren and Davidoff 1997; Modesti, Bertolozzi et al. 2005). Interestingly, 
genetically modified mice that take up excess glucose but also demonstrate enhanced 
glycolytic flux are, however, protected from glucotoxicity (Liao, Jain et al. 2002; 
Taegtmeyer, McNulty et al. 2002). Taken together, these data support our hyopthesis 
that intermediary glucose metabolite (G6P) accumulation may be imposing a metabolic 
stress on the heart and contributing to contractile dysfunction in an mTOR-dependent 
manner.  
 Rapamycin pretreatment rescued G6P-mediated cardiac dysfunction at increased 
workload. Rapamycin is well known for its ability to bind and disrupt the mTOR 
complexes (Yip, Murata et al. 2010). I now provide compelling evidence that its 
metabolic effects on the heart may mediate its inhibition of mTOR and its downstream 
targets, as well. Prolonged rapamycin treatment inhibits mTORC2 assembly, which 
prevents phosphorylation of Akt (Sarbassov, Ali et al. 2006), a known regulator of 
glucose uptake in the heart (Cong, Chen et al. 1997). Therefore, not surprisingly, I 
observed that rapamycin administration reduced Akt phosphorylation and blunted rates 
of glucose uptake at increased workload. In doing so, rapamycin prevented the mismatch 
between glucose uptake and oxidation, depleted intracardiac G6P, inhibited the 
phoshporylation of mTOR and its downstream targets, and improved contractile function 
at high workload. 
 Interestingly, rapamycin improved cardiac power despite lowering rates of 
myocardial glucose uptake and oxidation to levels nearly equivalent to hearts beating 
against a normal workload may seem paradoxical. One may ask: how can the heart 
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perform better when it is oxidizing less substrate? From an energetic perspective, the 
data suggests that the increased energy requirements of hearts subjected to high 
workload, which are met by the oxidation of carbohydrates, may no longer be necessary 
in hearts of rats treated with rapamycin. I will expand upon the mechanism in the next 
chapter. The improvement in cardiac power observed in rapamycin treated rats also 
gives credence to the hypothesis that the hypertrophic process may not be necessary to 
maintain systolic function in hearts subjected to increased workload (Hill, Karimi et al. 
2000). 
 While metformin is known to improve cardiac function in murine models of 
heart failure (Gundewar, Calvert et al. 2009; Yin, van der Horst et al. 2011), its ability to 
alleviate contractile dysfunction in hearts subjected to increased workload has yet to be 
studied. I demonstrate that when administered directly to the heart ex vivo or 
systemically in vivo, metformin enhances the heart’s capacity to oxidize glucose, reduces 
intracardiac G6P levels, inhibits mTOR activation and improves contractile function in a 
dose-dependent manner. Therefore, I propose that like rapamycin, metformin 
metabolically protects hearts subjected to increased workload and in doing so may 
account for improving survival in diabetic patients with heart failure (Aguilar, Chan et 
al. 2011). Whereas metformin decreases substrate supply to the heart by lowering 
circulating nonesterified free fatty acids, inhibiting hepatic gluconeogenesis, improving 
peripheral glucose uptake, and improving energy homeostasis  (Wang, Zhang et al. 
2011), insulin sensitizers, such as thiazolidinediones (TZDs) increase substrate uptake to 
the insulin-responsive heart.  Despite decreasing circulating free fatty acid levels, TZDs 
therefore further flood the metabolically overloaded heart as we have previously 
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demonstrated by measuring rates of substrate utilization in the ex vivo perfused heart 
(Golfman, Wilson et al. 2005). It is possible that this contributes to explaining the 
increased risk of heart failure and adverse cardiac events associated with their use 
(Dormandy, Charbonnel et al. 2005) (Lincoff, Wolski et al. 2007; Graham, Ouellet-
Hellstrom et al. 2010).  
  Our studies also implicate a critical role for dysregulated glucose metabolism in 
cardiac growth signaling in human heart failure.  I observed a significant decrease in 
G6P accumulation in human heart failure tissue samples after LVAD support (as was 
seen in our rodent hearts treated with rapamycin and metformin). We have previously 
observed a trend for decreased myocardial glycogen content in failing human hearts after 
mechanical unloading (Razeghi and Taegtmeyer 2004) and more recently, proteomic 
analysis has revealed an upregulation of proteins involved in glycolysis, energy, and 
oxidative metabolism in LVAD supported patients (de Weger, Schipper et al. 2011). 
Moreover, our finding that markers of mTOR activation are downregulated following 
LVAD support is also consistent with studies by Baba et al. that reported decreased 
myocyte size and decreased activity of Akt with mechanical unloading (Baba, Stypmann 
et al. 2003). Taken together, these studies suggest that mechanical unloading with 
LVAD may also metabolically unload the heart by promoting a re-coupling of glucose 
uptake and oxidation, preventing intermediary metabolite accumulation, and conserving 
energy in the failing heart in an mTOR-dependent manner. To date, no reliable marker 
exists to predict which patients will benefit most from LVAD placement. Unfortunately, 
in our 11 patient samples there is no data available on cardiac ejection fraction at time of 
explantation. However, it is tempting to speculate that a metabolic parameter, such as 
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cardiac G6P levels, could be useful in identifying which patients would benefit most 
from LVAD placement. Due to the difficulty in obtaining myocardial tissue samples and 
assessing substrate flux in humans, it remains difficult to more accurately assess the 
effects of mechanical unloading on myocardial energetics and glucose utilization in the 
heart.   
 In conclusion, in this chapter I have demonstrated that metabolic remodeling 
precedes, triggers, and sustains structural remodeling of the heart. Specifically, I have 
identified that dysregulated glucose metabolism (uptake in excess of oxidation) and 
subsequent G6P accumulation mediate load-induced mTOR activation and contractile 
dysfunction. Our study highlights the importance of intermediary metabolism as a rich 
source of signals for cardiac growth and demonstrate the potential to reduce internal 
work and improve cardiac efficiency by targeting the metabolic axis in load-induced 
heart disease. 
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CHAPTER 4: SUSTAINED mTOR ACTIVATION INDUCES ENDOPLASMIC 
RETICULUM STRESS 
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4.1 Introduction 
 
 While the previous chapter detailed the upstream metabolic regulation of ‘load-
induced’ mTOR signaling, this chapter focuses on its downstream consequences. Stated 
otherwise, it seeks to answer the question: why does sustained mTOR activation lead to 
contractile dysfunction both in vivo and ex vivo? Phosphorylation of mTOR and its 
downstream targets triggers protein synthesis by promoting mRNA translation and 
ribosomal biogenesis (Mayer and Grummt 2006) and inhibiting protein degradative 
processes such as autophagy (Kroemer, Marino et al. 2010) and the ubiquitin proteasome 
system (Depre, Wang et al. 2006; Depre, Powell et al. 2010). 
 Normal contractile function of the cardiomyocyte requires all synthesized 
proteins to be properly folded (Sanbe, Osinska et al. 2005). Molecular chaperones 
located in the endoplasmic reticulum (ER) ensure the proper folding of many proteins by 
identifying hydrophobic segments of misfolded or unfolded proteins and refolding them 
into functioning proteins. In doing so, the ER is able to prevent the formation of toxic 
protein aggregates in the unstressed heart (Ron and Walter 2007). Mice expressing 
mutant molecular chaperone proteins develop cardiomyopathy secondary to the 
accumulation of protein aggregates (Maloyan, Osinska et al. 2009). Fortunately, with the 
notable exception of cardiac amyloidosis, not many primary protein-folding disorders 
have been identified. However, proteotoxicity in the stressed heart may be more 
common that generally assumed and it may be metabolically regulated.  
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 In the in vivo hemodynamically stressed heart, activation of mTOR drives protein 
synthesis and floods the ER with unfolded and misfolded proteins beyond its protein 
folding capacity leading to ER stress (Okada, Minamino et al. 2004). Histological 
examination has clearly demonstrated marked development of the ER in hypertrophic 
and failing hearts (Ferrans, Jones et al. 1975). I, therefore, explored whether increased 
glucose uptake (and subsequent accumulation of intermediary metabolites of glucose 
such as G6P) induces contractile dysfunction by generating ER stress in the stressed 
heart. Contractile dysfunction in cardiac hypertrophy and heart failure has been linked to 
elevated glucose uptake in numerous humans and animal models (Bishop and Altschuld 
1970; Taegtmeyer and Overturf 1988; Zhang, Duncker et al. 1995)  in an insulin-
independent manner (Allard, Wambolt et al. 2000). However, it has yet to be studied 
whether the mechanism involves dysregulated protein synthesis. In yeast, a number of 
the molecular chaperones that assist in protein folding in the ER are responsive to 
glucose and appropriately named glucose-regulated proteins (Groenendyk, Sreenivasaiah 
et al. 2010). 
 The two main objectives of the experiments conducted in this chapter were to: 1) 
Determining whether sustained mTOR activation leads to ER stress in the heart in a 
substrate-dependent manner. 2) Identifying whether the ER stress response can be 
targeted to improve contractile function in the stressed heart. Specifically, I tested the 
hypothesis that signals generated by glucose metabolism impair contractile function via 
mTOR-mediated ER stress in the heart. I tested this hypothesis by first assessing cardiac 
power and ER stress in hearts subjected to high workload and perfused with glucose in 
order to confirm that G6P-mediated mTOR activation is associated with ER stress and 
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contractile dysfunction. Next, I alleviated ER stress pharmacologically by adding 4-
Phenylbutyrate (4PBA) to the perfusate in order to determine whether relieving ER 
stress improves cardiac function despite continued G6P-mediated mTOR activation. 
Lastly, I assessed whether rapamycin pretreatment can prevent ER stress and improve 
cardiac function in hearts subjected to high workload. These experiments were meant to 
establish changes in glucose metabolism, and subsequent G6P accumulation, as a 
regulator of ER stress and contractile function in hearts subjected to high workload and 
determine whether it is possible to pharmacologically prevent G6P-mediated ER stress.  
 
4.2 Results 
 
4.2.1 Load-induced ER Stress Requires Glucose and mTOR Activation 
 
 Because of mounting evidence that dysregulated mTOR activation induces ER 
stress (Ozcan, Ozcan et al. 2008), I elucidated whether the induction of ER stress was 
responsible for the decline in cardiac power in hearts perfused with glucose at high 
workload. Transcription of the ER chaperones GRP78, GRP94, and ERp72 are increased 
when a cell exhibits ER stress. Neither high workload with NCS nor glucose at normal 
workload increased markers of ER stress (Fig. 4.1A). However, perfusion at high 
workload with glucose as the only substrate induced a 1.9-fold increase in GRP78, 1.8-
fold increase in GRP94, and a 1.6-fold increase in ERP72 mRNA expression compared 
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to hearts perfused with NCS at normal workload (Fig. 4.1A). It was also associated with 
an increase in GRP78 protein level (Fig. 4.1B). Because prolonged ER stress causes 
cellular damage and induces apoptosis I also assessed levels of GADD153/CHOP, a 
marker of ER-associated apoptosis. GADD153/CHOP protein levels were unchanged 
under all untreated conditions suggesting the absence of apoptosis (Fig. 4.1B). I used 
thapsigargin as a positive control for ER stress. Thapsigargin is a non-competitive 
inhibitor of SERCA2a (sarco-endoplasmic reticulum calcium ATP-ase) that raises 
cytosolic calcium and inhibits the fusion of autophagosomes with lysosomes. 
 Besides for unfolded and misfolded proteins, ischemia is a known trigger of the 
ER stress response. In order to determine whether ischemia was contributing to the 
imposition of ER stress in hearts perfused with glucose at high workload, I assessed 
lactate release. Lactate release did not significantly change with high workload or with 
rapamycin treatment (Fig 4.2). 
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Figure 4.1 Hearts perfused with glucose at high workload show evidence for ER 
stress. (A) qRT-PCR analysis of ER stress  markers in isolated working rat hearts. 
Data is presented as fold change in ER stress markers compared to hearts perfused 
with NCS at normal workload. Hearts perfused with glucose at high workload 
undergo a nearly two-fold increase in markers of ER stress. (B) Representative 
western blots demonstrate increased GRP78 protein level in hearts perfused with 
glucose at high workload. n=5-8, *p<0.05 compared to hearts perfused with NCS at 
normal high workload and glucose at normal workload  
103 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Lactate release is unchanged with workload or rapamycin treatment 
in isolated working hearts perfused with glucose. Lactate release was assessed in 
coronary effluent samples drawn every 5 minutes throughout the perfusion. Data are 
presented as mean ± SEM under each condition. n=5-8 for each group 
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4.2.2 Pretreatment with Rapamycin or Metformin Inhibits ER Stress and Prevent 
Contractile Dysfunction at High Workload 
 
 In order to determine whether ER stress was a consequence of mTOR activation, 
I assessed markers of ER stress in hearts of animals treated with either AMPK-activator 
metformin or mTOR-inhibitor rapamycin prior to being perfused with glucose at high 
workload. Increases in GRP78, GRP94, ERp72 mRNA expression and GRP78 protein 
level were prevented in hearts subjected to high workload in animals pretreated with 
rapamycin or metformin treatment prior to perfusion (Fig. 4.3A-B).  
 To determine whether ER stress contributed to the decline in cardiac power in 
hearts perfused with glucose at increased workload, perfusions were repeated in the 
presence of the ER stress-relieving agent phenylbutyrate (PBA). PBA reduced mRNA 
expression levels of GRP78, GRP94, and ERp72 (Fig. 4.3A), reduced protein level of 
GRP78 (Fig. 4.3B), and was associated with a 27% increase in cardiac power in hearts 
perfused at increased workload with glucose (Fig. 4.3C). Taken together, these data 
suggest that ER stress is, at least partially responsible for the decline in contractile 
function associated with G6P-mediated mTOR activation. PBA had no effect on cardiac 
power at normal workload. PBA also had no effect on G6P accumulation, mTOR or 
p70S6K phosphorylation (Fig. 4.3D). Hearts perfused at normal workload with ER 
stress inducing agent thapsigargin, an inhibitor of SERCA2a, were used as a positive 
control. 
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Figure 4.3 ER Stress is relieved with rapamyin, metformin, and PBA. Relief of ER 
stress improves contractile function in hearts perfused with glucose at high workload. 
(A) qRT-PCR analysis of ER stress in isolated working rat hearts. Data is presented as fold 
change in ER stress markers compared to hearts perfused with NCS at normal workload. 
Hearts perfused with glucose at high workload undergo a nearly two-fold increase in markers 
of ER stress, which is alleviated by rapamycin, metformin, and phenylbutyrate (PBA). (B) 
Representative western blots demonstrate an inhibition of mTOR signaling and GRP78 
protein level in hearts treated with rapamycin or metformin. Hearts treated directly with ER 
stress reliever PBA exhibited a decrease in GRP78 protein level independent of changes in 
mTOR signaling. Taken together, these data suggest that the induction of ER stress is 
downstream of mTOR activation and prevented by rapamycin and metformin treatment. (C) 
Cardiac power in the isolated working rat heart perfused with glucose in the presence and 
absence of PBA. PBA improved cardiac power at high workload. (D) G6P accumulation in 
isolated working rat hearts freeze clamped at the end of the perfusion protocol. n=5-8. Data 
are presented as mean ± SEM * p< 0.05  
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 Next we performed microarray analyses to delineate whether systemic 
pretreatment with either rapamycin or metformin or phenylbutyrate addition to the 
perfusion medium could transcriptionally activate other genes responsible for contractile 
function in stressed hearts perfused with glucose. Cluster analysis showed no significant 
clusters of genes similarly regulated by all three treatment groups (Fig. 4.4A). The 
number of genes differentially regulated by each treatment group are listed in Fig. 4.4B 
and the fold-change of the four genes downregulated by each of the three treatments is 
listed in Fig. 4.4C. One gene has yet to be identified and the other three genes (Scgb1a1, 
Sp6, and Bpifa1) are not known to be associated with any changes in glucose 
metabolism or protein turnover. Scgb1a1, the gene that encodes uteroglobin, has no 
physiological role known in either rodents or humans and is named for its role in binding 
progesterone in uterus of rabbits. Sp6 encodes a transcription factor with no known role 
in the heart. The Bpifa1 gene is expressed in the nasopharynx during the inflammatory 
response. Although this approach does not capture potential changes in changes that 
could occur at the post-translational level with all three treatments, these results support 
the hypothesis that an alternative mechanism is unlikely to be responsible for improving 
contractile function in stressed hearts perfused with glucose.  
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Figure 4.4 Transcriptome analysis of stressed hearts treated with rapamycin, 
metformin, and phenylbutyrate  (A) Representative heat map of microarray analyses of 
rat hearts treated with rapamycin, metformin, or phenylbutyrate prior to being perfused 
with glucose at high workload (B) Venn diagram of the number of genes identified that 
are differentially regulated by each treatment.  (C) Genes regulated by phenylbutyrate, 
metformin, and rapamycin treatment. Scgb1a1 (Secretoglobin, family 1A, member 1 
(uteroglobin)), Sp6 (Sp6 transcription factor), Bpifa1 (BPI fold containing family A, 
member 1) n=3 rats per group. Rapa, pretreated with rapamycin; METFMN, pretreated 
with metformin; PHNYLBUT, phenylbutryrate added to the perfusion medium.  
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4.2.3 Markers of ER Stress are Downregulated in Failing Human Hearts 
Following Mechanical Unloading with LVAD 
 
 In order to investigate whether changes in cardiac glucose metabolism were 
accompanied by changes in ER stress, ER chaperones GRP78, GRP94, and ERp72 were 
assessed. Protein levels of GRP78, GRP94, and ERp72 were decreased after mechanical 
unloading with LVAD in the same group of patients described before (Fig. 4.4).  
 
 
 
 
 
 
 
 
Figure 4.5. Mechanically unloading failing human hearts reduces 
markers of ER stress. Representative western blots demonstrate a 
reduction in markers of ER stress (ERP72, GRP94, GRP78) in failing 
human hearts after mechanical unloading, as well. n=11 paired samples.   
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4.2.4 Role of Autophagy in G6P-mediated mTOR activation 
 
 Protein quality control is highly regulated by autophagy in an mTOR-dependent 
manner. I therefore wanted to know the whether markers of autophagy were dynamically 
regulated with acute changes in workload and whether pretreatment with rapamycin 
could prevent these changes. At the protein level, no changes were appreciated in hearts 
of animals treated with rapamycin treatment prior to perfusion at high workload with 
glucose (Fig. 4.6). The autophagic process is very time-dependent and an assessment of 
LC3 localization into discrete punctate cytoplasmic dots (seen by immunofluoresence) 
or protein levels of LCIII and Beclin at earlier and later time-points would be necessary 
to confirm whether or not autophagy is regulated by glucose-dependent mTOR 
activation.  
 
Figure 4.6 Markers of autophagy are unchanged with rapamycin treatment in 
hearts stressed with an acute increase in workload. Markers of autophagy (LC3, 
Beclin) were unchanged by rapamycin treatment prior to being subjected to high 
workload in ex vivo isolated working hearts as described in Table 2.2. NCS refers to 
hearts perfused with the non-carbohydrate substrates acetoacetate (7.5 mM) and 
propionate (5 mM), glucose refers to the hearts perfused with glucose as the only 
substrate.   
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4.3 Discussion 
  
  In hearts subjected to high workload, mTOR activation is associated with 
cardiac hypertrophy and contractile dysfunction (Shioi, McMullen et al. 2003). Even in 
Drosophila, dTOR (drosophila TOR) overactivity is associated with cardiac dysfunction 
and decreased lifespan (Topisirovic and Sonenberg 2010). Sustained mTOR activation 
synthesizes proteins beyond the folding capacity of the endoplasmic reticulum (ER), and 
induces ER stress (Glembotski 2008). By evaluating the ER chaperone expression as a 
marker of ER stress, I demonstrate that load-induced ER stress in the heart is 
metabolically regulated. Transcriptional activation of genes regulating the ER stress 
response is significantly increased in hearts subjected to high workload only when 
perfused with glucose (which leads to G6P accumulation and contractile dysfunction). 
Although the mechanism by which ER stress causes contractile dysfunction has yet to be 
defined, I suspect that it involves a perturbation of normal calcium handling. Contractile 
dysfunction in isolated rodent hearts perfused with high concentrations of glucose is 
associated with the presence of abnormal calcium transients (Tang, Cheng et al. 2010). 
Because the ER regulates calcium flux and excitation-contraction coupling, it is 
conceivable that G6P-mediated ER stress is responsible for impairing contractile 
function by inducing abnormal calcium transients. Specifically, I suggest a critical role 
for ER chaperone GRP78, which is involved in calcium transport from the ER to the 
mitochondria (Dudek, Benedix et al. 2009). In our studies, GRP78 gene expression and 
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protein levels were dynamically upregulated with even an acute increase in workload for 
30 min in the presence of glucose. Direct relief of ER stress with chemical chaperone 
PBA rescued contractile function in hearts perfused with glucose at high workload. PBA 
is already approved by the U.S. Food and Drug Administration for urea cycle disorders 
and safely used in clinical trials to treat cystic fibrosis (Rubenstein and Zeitlin 1998). It 
may have therapeutic benefit in load-induced heart disease, as well.  
 Rapamycin pretreatment also rescues G6P-mediated ER stress and cardiac 
dysfunction at increased workload. By blunting rates of glucose uptake at increased 
workload and preventing the mismatch between glucose uptake and oxidation, it 
depletes intracardiac G6P, inhibits mTOR, and prevents the imposition of ER stress.  
 However, rapamycin treatment also improves cardiac power despite lowering 
rates of myocardial glucose uptake and oxidation to unstressed levels. From an energetic 
perspective, this suggests that the increased energy requirements of hearts subjected to 
high workload, which are met by the oxidation of carbohydrates, may largely be 
responsible for fueling protein turnover and protein quality control (“internal work”). 
Protein turnover utilizes roughly 15-20% of a cell’s energy in the resting state (Waterlow 
1984), and at least 3 times more energy during times of growth (Laurent and Millward 
1980) (Lane and Martin 2010). It is, therefore, tempting to speculate that the energy 
conserved by rapamycin’s inhibition of protein synthesis and ER stress improves cardiac 
efficiency and contributes to its ability to reverse load-induced cardiac dysfunction 
(Shioi, McMullen et al. 2003; McMullen, Sherwood et al. 2004; Marin, Keith et al. 
2011). Furthermore, the improvement in cardiac power observed in rapamycin treated 
rats gives credence to the hypothesis that the hypertrophic process may not be necessary 
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to maintain systolic function in hearts subjected to increased workload (Hill, Karimi et 
al. 2000). Our results offer a new perspective on the energy cost of protein synthesis and 
protein quality control. 
 Metformin has been shown to inhibit ER stress in isolated mouse aortas from 
mice fed an athrogenic diet (Dong, Zhang et al. 2010) and in cardiomyocytes subjected 
to ER stress by reperfusion after hypoxia (Yeh, Chen et al. 2010). While metformin is 
known to improve cardiac function in murine models of heart failure (Gundewar, Calvert 
et al. 2009; Yin, van der Horst et al. 2011) its ability to alleviate ER stress in hearts 
subjected to increased workload has yet to be studied. I demonstrate that metformin 
inhibits G6P-mediated mTOR activation in a dose-dependent manner and protects 
against load-induced ER stress.  When administered systemically, metformin also 
improves the oxidative capacity of the heart, blunts G6P accumulation, and improves 
cardiac function. Therefore, I propose that like rapamycin, metformin metabolically 
protects hearts subjected to increased workload and in doing so may account for 
improving survival in diabetic patients with heart failure (Aguilar, Chan et al. 2011). 
 Indeed, markers of ER stress are upregulated in failing human hearts (Okada, 
Minamino et al. 2004). I now report that in hearts from a cohort of 11 non-diabetic 
patients with idiopathic heart failure, mechanical unloading with an LVAD reduces 
intracardiac G6P levels and protein levels of ER stress markers. Our studies in the rodent 
heart implicate a critical role for dysregulated glucose metabolism and toxic 
intermediary metabolite accumulation in the induction of ER stress. Similarly, I 
observed a significant decrease in G6P accumulation after LVAD support. We have 
previously observed a trend for decreased myocardial glycogen content in failing human 
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hearts after mechanical unloading (Razeghi and Taegtmeyer 2004) and more recently, 
proteomic analysis has revealed an upregulation of proteins involved in glycolysis, 
energy, and oxidative metabolism in LVAD supported patients (de Weger, Schipper et 
al. 2011). Taken together, these studies support our findings and suggest that mechanical 
unloading promotes a re-coupling of glucose uptake and oxidation, prevents 
intermediary metabolite accumulation, and conserves energy in the failing heart by 
reducing ER stress. Due to the difficulty in obtaining myocardial tissue samples and 
assessing substrate flux in humans, it remains difficult to more accurately assess the 
effects of mechanical unloading on myocardial energetics and glucose utilization in the 
heart.   
 When supplied with excess substrate by high fat feeding, mice become insulin 
resistant and skeletal muscle, liver and adipocytes all undergo ER stress (Li, Huang et al. 
2012) (Gregor and Hotamisligil 2007; Deldicque, Cani et al. 2010). Oral administration 
of ER stress relieving agent 4-phenyl butyric acid (PBA) to obese mice restores systemic 
insulin sensitivity, normalizes serum glucose levels, resolves fatty liver disease, and 
enhances insulin action in liver, muscle, and adipose tissues (Ozcan, Yilmaz et al. 2006). 
Taken together, these data support our conclusions that excess substrate supply may lead 
to cellular dysfunction by inducing ER stress. Moreover, direct relief of ER stress may 
have therapeutic potential both systemically and in the heart (Engin and Hotamisligil 
2010). Interestingly, FDA-approved tyrosine kinase inhibitors imatinib and sunitinib 
have recently been found to have ER stress relieving properties, as well, and both have 
prevented and reversed obese mice from developing diabetes and heart failure (Louvet, 
Szot et al. 2008; Han, Lerner et al. 2009). 
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 In a cohort of 11 morbidly obese patients (BMI 51.3 ± 3.0 kg/m2), markers of ER 
stress were elevated in both adipose tissue and liver. Moreover, one year after gastric 
bypass surgery (which forces caloric restriction and a significant reduction in exogenous 
fuel supply to the body), markers of ER stress such as GRP78 were reduced in adipose 
tissue and liver, which directly correlated with reversal of insulin resistance (Gregor, 
Yang et al. 2009). In the heart, both diet-induced weight loss and weight-loss surgery 
lead to a reduction in left ventricular mass, regression of cardiac hypertrophy, and 
improvement in midwall fractional shortening (Rider, Francis et al. 2009; Algahim, Lux 
et al. 2010; Owan, Avelar et al. 2011). By reducing substrate supply to the heart, it is 
plausible that the beneficial cardiovascular effects may be mediated by regulating 
glucose metabolism, mTOR activation, and ER stress in the heart.  
 
4.4 Limitations  
  
 I am the first to admit that my studies are not without limitations. First, there are 
significant differences between the human and rodent heart that are worth mentioning. 
The human heart rate and ejection fraction is significantly less than that of the rodent 
heart. Also, acute increases in workload via aortic banding in vivo or doubling afterload 
ex vivo may not accurately mimic the chronic, low levels of hemodynamic stress induced 
by pathological stimuli that induce cardiac hypertrophy. Moreover, while it is plausible 
that abnormal calcium handling by the sarcoplasmic reticulum may be responsible for 
ER stress induced contractile dysfunction in the rodent heart, it is less clear whether the 
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same mechanism would exist in the human heart. Calicum handling in rodents relies 
much more heavily on transport through the sarcoplasmic reticulum than the human 
heart, which seems to rely more heavily on transsarcolemmal calcium transport (Berenji, 
Drazner et al. 2005). In spite of these limitations and because the structural, functional, 
and metabolic changes that occur in the rodent heart mimic those of the human heart, I 
believe the work in this dissertation has identified glucose metabolism (and specifically 
glucose 6-phosphate) as a dynamic regulator of myocardial protein synthesis, ER stress 
and possibly also protein turnover as well as expanded the role of energy substrate 
metabolism from simply being a provider of ATP to a regulator of cardiac protein 
synthesis and growth as well. 
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 The heart is a dynamic organ with an enormous capacity to respond to stress. The 
heart also remodels metabolically and structurally before it goes into heart failure. The 
question I began to address in my dissertation tried to fill an important gap in the current 
knowledge of cardiac physiology: Does the early metabolic remodeling process regulate 
the structural and functional remodeling process in the heart? In a series of different 
experimental strategies I provided evidence in support of our hypothesis that metabolic 
remodeling (which is potentially reversible) regulates functional and structural 
remodeling (which is largely irreversible) and discovered that it is both deleterious and 
preventable. 
 With help from collaborators at the University of Virginia, we first quantitatively 
demonstrated in vivo that enhanced glucose uptake in the heart accompanies load-
induced contractile dysfunction prior to the presence of structural changes. Stated 
otherwise, metabolic remodeling precedes structural remodeling of the heart and 
accompanies load-induced contractile dysfunction. Before beginning my dissertation 
project, numerous studies had quite convincingly provided evidence that load-induced 
mTOR signaling mediates cardiac growth (Shioi, McMullen et al. 2003; McMullen, 
Sherwood et al. 2004; Zhang, Contu et al. 2010). However, every study largely ignored 
the fact that changes in workload are accompanied by instantaneous changes in cardiac 
substrate metabolism (Goodwin, Taylor et al. 1998), which could be contributing to 
regulating ‘load-induced’ hypertrophy and contractile dysfunction as well. Indeed, my 
findings in the isolated working heart ex vivo demonstrate that an acute increase in 
workload is not sufficient to activate mTOR in the absence of glucose, suggesting that 
‘load-induced’ hypertrophic signaling through mTORC1 is glucose-dependent. A 
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number of genetically engineered mouse hearts that take up glucose in excess of its 
oxidative capacity also hypertrophy and provide evidence in support of our hypothesis, 
as well (Domenighetti, Danes et al. 2010; Ellis, Mentock et al. 2011; Liu, Yu et al. 
2011). 
 More specifically, I propose that mTORC1 is activated by the metabolic signal 
G6P. I dissected the load and substrate-dependence of mTORC1 signaling in the heart ex 
vivo and determined that doubling the workload alone triggers PI3K, Akt, and minimal 
Akt-dependent phosphorylation of TSC2 at Ser939 phosphorylation, both in the presence 
and absence of glucose. However, complete ‘load-induced’ mTORC1 activation and 
contractile dysfunction requires not only Akt-dependent phosphorylation of TSC2 at 
Ser939 but also a downregulation of AMPK-dependent phosphorylation of TSC2 at 
Ser1387 (Shaw, Bardeesy et al. 2004), which occurs with G6P accumulation (in hearts 
perfused with glucose as the only substrate at high workload).  
 In order to determine the consequences of G6P-dependent mTOR activation, I 
focused my attention on the role of endoplasmic retiticulum (ER) stress. When subjected 
to hemodynamic stress (continued pumping against high workload), increased rates of 
protein synthesis flood the ER with unfolded and misfolded proteins beyond its capacity 
to cope with the load, which leads to ER stress (Glembotski 2008). Whether increased 
glucose uptake and accumulation as G6P causes contractile dysfunction by generating 
ER stress remains unknown. I therefore investigated whether when subjected to high 
workload, the metabolic remodeling process (increased reliance upon glucose) 
contributes to a decline in cardiac function by generating ER stress.  
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 Indeed, it does. Expression levels of three early response markers of ER stress 
(GRP78, ERp72, and GRP94) all correlated with G6P-mediated mTOR activation and 
contractile dysfunction ex vivo. Furthermore, both rapamycin and metformin 
pretreatment, which inhibited G6P-mediated mTOR activation and rescued contractile 
function, also prevented the upregulation of markers of ER stress at both the 
transcriptional and translational level. Similarly, pharmacologic alleviation of ER stress 
with chemical chaperone 4-Phenylbutyrate (4PBA) improved cardiac function, as well. 
Alleviation of ER stress improved contractile function despite elevated G6P levels, 
however, suggesting that the induction of ER stress is downstream of G6P-mediated 
mTOR activation. Taken together, these data suggested that G6P-mediated mTOR 
activation leads to ER stress and impairs contractile function in hearts subjected to high 
workload.  
 I believe my findings also shed new light on the energetic cost of protein 
turnover in the stressed heart. Rather unexpectedly, rapamycin treatment improved 
cardiac power despite lowering rates of myocardial glucose uptake and oxidation to 
unstressed levels. From an energetic perspective, this suggests that the increased energy 
requirements of hearts subjected to high workload, which are met by the oxidation of 
carbohydrates, may largely be responsible for fueling protein turnover and protein 
quality control (“internal work”). Protein turnover utilizes roughly 15-20% of a cell’s 
energy in the resting state (Waterlow 1984), and at least 3 times more energy during 
times of growth (Laurent and Millward 1980). It is, therefore, tempting to speculate that 
the energy conserved by rapamycin’s inhibition of protein synthesis and ER stress 
improves cardiac efficiency and contributes to its ability to reverse load-induced cardiac 
120 
dysfunction (Shioi, McMullen et al. 2003; Sancak, Peterson et al. 2008; Marin, Keith et 
al. 2011). Furthermore, the improvement in cardiac power observed in rapamycin treated 
rats gives credence to the hypothesis that the hypertrophic process may not be necessary 
to maintain systolic function in hearts subjected to increased workload (Hill, Karimi et 
al. 2000). Our results offer a new perspective on the energy cost of protein synthesis and 
protein quality control. 
 My studies have also demonstrated a novel mechanism that contributes to the 
improvement in contractile function known to occur in the stressed heart with metformin 
treatment. Metformin has been shown to inhibit ER stress in isolated mouse aortas from 
mice fed an athrogenic diet (Dong, Zhang et al. 2010) and in cardiomyocytes subjected 
to ER stress by reperfusion after hypoxia (Yeh, Chen et al. 2010). While metformin is 
known to improve cardiac function in murine models of heart failure (Gundewar, Calvert 
et al. 2009; Yin, van der Horst et al. 2011), its ability to alleviate ER stress in hearts 
subjected to increased workload had previously not been studied. I demonstrate that 
metformin inhibits G6P-mediated mTOR activation in a dose-dependent manner and 
protects against load-induced ER stress.  When administered systemically, metformin 
also improves the oxidative capacity of the heart, blunts G6P accumulation, and 
improves cardiac function. Therefore, I propose that like rapamycin, metformin 
metabolically protects hearts subjected to increased workload and in doing so may 
account for improved survival in diabetic patients with heart failure (Aguilar, Chan et al. 
2011). These data may have wide implications outside of cardiovascular disease, as well. 
Metformin is associated with increased survival in various types of cancer although the 
mechanism remains unknown (Dowling, Goodwin, et al. 2011). Its well-studied effects 
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of activating AMPK, reducing plasma insulin levels, and inhibiting hepatic 
gluconeogenesis likely reduce G6P accumulation and subsequent mTOR activation.
 Next, one must consider the possible clinical relevance of my findings. Despite 
the recent advances in cardiovascular medicine, the majority of patients with heart 
disease still progress to end-stage heart failure, for which treatment is largely limited to 
cardiac transplantation. As the need for transplantable hearts continues to far exceed the 
supply of available organs, left ventricular assist devices (LVADs) are implanted with 
increased frequency. Although initially meant to serve as a ‘bridge to transplantation’, 
and not necessarily as destination therapy, many patients experienced functional 
improvement without requiring a heart transplantation but the mechanism remains 
largely unknown. Transcriptional analysis of metabolic genes revealed a reversal of the 
failing human heart to the fetal gene program (Razeghi, Young et al. 2001) and a partial 
reversal after implantation of an LVAD (Razeghi, Young et al. 2002). However, 
proteomic analysis has now shown an upregulation of proteins involved in glycolysis, 
energy, and oxidative metabolism in LVAD supported patients (de Weger, Schipper et 
al. 2011). Taken together, these data suggest improved metabolic capacity with LVAD 
implantation. Both the mTOR signaling pathway and markers of ER stress are also 
upregulated in the hypertrophied and failing human heart. I have found that in hearts 
from a cohort of 11 patients with idiopathic heart failure, mechanical unloading with a 
left ventricular assist device (LVAD) reduces protein levels of ER stress markers. 
Moreover, consistent with our data that implicate a critical role for dysregulated glucose 
metabolism and intermediary metabolite accumulation in the induction of ER stress, I 
observed a significant decrease in G6P accumulation after LVAD support. These studies 
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suggest that mechanical unloading may promote a re-coupling of rates of glucose uptake 
and oxidation prevent intermediary metabolite accumulation and contribute to a 
reduction of ER stress in the failing heart.  
 However, a number of important questions remain. This is a common feature of 
all novel research. The first question is: What is the exact molecular mechanism by 
which G6P modulates TSC2 to promote mTOR activation? Two probable mechanisms 
by which G6P may regulate TSC2 include: 1) modulation of one or several kinases that 
act on TSC2 or 2) allosteric regulation of TSC2 itself. The generation and transfection 
into of constructs containing mutated phosphorylation sites into stressed cardiomyocytes 
would help determine whether G6P modulates TSC2 or one of its upstream kinases. 
Phosphorylation site mutations on TSC2 have been used previously to investigate 
mTORC1 activation (Huang and Manning 2008). It is plausible that G6P promotes the 
phosphorylation of TSC2 or one of its upstream kinases in a manner similar to its ability 
to control the phosphorylation state of glycogen synthase (Huang, Wilson et al. 1997). 
Radiolabeled binding assays can determine whether G6P promotes mTOR activation by 
directly binding itself to TSC2 or one of its upstream kinases by pulling down the 
candidate kinases from rat heart lysates by immunoprecipitation, incubating with 
uniformly labeled [14C]-G6P, and assaying for radioactivity. This approach has 
previously been used to identify novel binding of proteins in the Akt/mTOR pathway to 
small non-protein molecules such as microfilaments (Zhu, Rosenblatt et al. 2011). 
 The second question is: By which mechanism does ER stress causes contractile 
dysfunction? I suspect the mechanism involves a perturbation of proper calcium cycling 
in and out of the cardiomyocytes specialized ER, the sarcoendoplasmic (SR) reticulum. 
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The SR is a known regulator of calcium flux and excitation-contraction coupling in the 
cardiomyocyte. Indeed, contractile dysfunction in rodent hearts perfused with high 
concentrations of glucose has already been associated with the presence of abnormal 
calcium (Hu, Belke et al. 2005). It is conceivable that this may have been mediated by 
ER stress. Moreover, mice with cardiac overexpression of the SR Ca2+ transporter 
(sarco/endoplasmic reticulum Ca2+-ATPase, SERCA) demonstrate improved cardiac 
function compared to wild type mice when subjected to aortic banding (Suarez, Gloss et 
al. 2004). Assessing glucose metabolism, mTOR activation, and markers of ER stress in 
these mice would help determine the exact mechanism by which ER stress induces 
contractile dysfunction in hearts subjected to high workload. 
 The third question is: How can the new knowledge on a metabolic signal driving 
another signaling pathway be leveraged to devise new therapeutic targets for the 
treatment of heart failure. This is perhaps the most challenging question for a young 
physician-scientist. The metabolic management of heart failure is the subject of reviews 
(Osterholt, Sen et al. 2012), clinical studies(Wallhaus, Taylor et al. 2001), and of meta-
analyses (Zhang, Lu et al. 2012). It is my hope that my work has laid the cornerstone for 
a new paradigm, just as Rudolph Schoenheimer wrote when he discovered the dynamic 
state of body constituents (Schoenheimer, 1942): “The new results imply that not only 
the fuel, but also the structural materials are in a steady state of flux. The classical 
picture must thus be replaced by one which takes account of the dynamic state of body 
structure” (page 64). 
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Conclusion 
 My findings demonstrate that metabolic remodeling precedes, triggers, and 
sustains structural remodeling of the heart. Specifically, I identify dysregulated 
glycolytic homeostasis as a novel regulator of contractile function, mTOR activation, 
and ER stress in response to increased cardiac workload. The study highlights the 
importance of intermediary metabolism, not only as energy providing substrates, but also 
as signals for driving cardiac growth. In doing so, it underscores the need to better 
metabolically protect patients with heart failure and sheds light on the metabolic effects 
of mechanically unloading the failing human heart. I believe these results have wide-
ranging implications for load-induced heart disease and based on the new findings, I 
speculate that targeting metabolism offers therapeutic promise in treating cardiovascular 
disease.  
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